SOS1 inhibitors and their use

Abstract

The present disclosure relates to a compound of formula (I) The present disclosure provides compounds of TIFF2024501280000094.tif4060, pharma- ceutically acceptable salts or stereoisomers, and their use in treating conditions, diseases or disorders in which the inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial, particularly in treating neoplastic diseases.The present disclosure also features compositions containing the same, as well as methods of using and making the same.

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to International Patent Application PCT / CN2020 / 138288, filed on 22 December 2020. The entire contents of the aforementioned application are incorporated herein by reference. [Background technology]

[0002] RAS family proteins, including KRAS (V-Ki-ras2 Kirsten rat sarcoma virus oncogene homolog), NRAS (neuroblastoma RAS virus oncogene homolog), and HRAS (Harvey mouse sarcoma virus oncogene), and any of their mutants, are low molecular weight GTPases present intracellularly in either a GTP-bound or GDP-bound state (McCormick et al., J. Mol. Med. (Berl)., 2016, Vol. 94 (No. 3): pp. 253-258; Nimnual et al., Sci. STKE., 2002, Vol. 2002 (No. 145): p. 36). RAS family proteins have weak intrinsic GTPase activity and slow nucleotide exchange rates (Hunter et al., Mol. Cancer Res., 2015, Vol. 13 (No. 9): pp. 1325-1335). Binding of GTPase-activating proteins (GAPs), such as NF1, increases the GTPase activity of RAS family proteins. The binding of guanine nucleotide exchange factors (GEFs), such as SOS1 (Son of Sevenless 1), promotes the release of GDP from RAS family proteins, enabling GTP binding (Chardin et al., Science, 1993, Vol. 260 (No. 51-12): pp. 1338-1343). When GTP-bound, RAS family proteins are active and associate with effector proteins including C-RAF and phosphoinositide 3-kinase (PI3K) to promote the RAF / mitogenic factor or extracellular signal-regulated kinase (MEK / ERK) pathway, the PI3K / AKT / rapamycin-mammalian target (mTOR) pathway, and the RaIGDS (Ral guanine nucleotide dissociation-stimulating factor) pathway (McCormick et al., J. Mol. Med. (Berl), 2016, Vol. 94 (No. 3): pp. 253-258; Rodriguez-Viciana et al., Cancer Cell. 2005, Vol. 7 (No. 3): pp. 205-206). These pathways influence a variety of cellular processes, such as proliferation, survival, metabolism, motility, angiogenesis, immunity, and growth (Young et al., Adv. Cancer Res., 2009, Vol. 102: pp. 1-17; Rodriguez-Viciana et al., Cancer Cell., 2005, Vol. 7 (No. 3): pp. 205-206).

[0003] Cancer-associated mutations in RAS family proteins suppress their endogenous and GAP-inducible GTPase activity, leading to an increase in the population of GTP-binding / active RAS family proteins (McCormick et al., Expert Opin. Ther. Targets., 2015, Vol. 19 (No. 4): pp. 451-454; Hunter et al., Mol. Cancer Res., 2015, Vol. 13 (No. 9): pp. 1325-1335). This then leads to sustained activation of downstream effector pathways of RAS family proteins (e.g., MEK / ERK, PI3K / AKT / mTOR, RaIGDS pathways). KRAS mutations (e.g., amino acids G12, G13, Q61, A146) are found in various human cancers, including lung cancer, colorectal cancer, and pancreatic cancer (Cox et al., Nat. Rev. Drug Discov., 2014, Vol. 13 (No. 11): pp. 828-851). Mutations in HRAS (e.g., amino acids G12, G13, Q61) and NRAS (e.g., amino acids G12, G13, Q61, A146) are also found in various human cancers, but are typically less frequent than KRAS mutations (Cox et al., Nat. Rev. Drug Discov., 2014, Vol. 13 (No. 11): pp. 828-851). Changes in RAS family proteins (e.g., mutations, overexpression, gene amplification) are explained as mechanisms of resistance to cancer drugs, such as the EGFR antibodies cetuximab and panitumumab (Leto et al., J. Mol. Med. (Berl). July 2014; Vol. 92 (No. 7): pp. 709-722) and the EGFR tyrosine kinase inhibitor osimertinib / AZD9291 (Ortiz-Cuaran et al., Clin. Cancer Res., 2016, Vol. 22 (No. 19): pp. 4837-47; Eberlein et al., Cancer Res., 2015, Vol. 75 (No. 12): pp. 2489-500).

[0004] Son of Sevenless 1 (SOS1) is the human homolog of Son of Sevenless, a protein originally identified in Drosophila (Pierre et al., Biochem. Pharmacol., 2011, Vol. 82 (No. 9): pp. 1049-1056; Chardin et al., Cytogenet. Cell. Genet., 1994, Vol. 66 (No. 1): pp. 68-69). The SOS1 protein consists of 1333 amino acids (150 kDa). SOS1 is a multi-domain protein with two tandem N-terminal histone domains (HD), followed by a Dbl homology region (DH), a Pleckstrin homology region (PH), a helical linker (HL), a RAS exchange motif (REM), a CDC25 homology region, and a C-terminal proline-rich domain (PR). SOS1 has two binding sites to RAS family proteins: a catalytic site that binds to GDP-binding RAS family proteins to promote guanine nucleotide exchange, and an allosteric site that binds to GTP-binding RAS family proteins to further enhance the catalytic GEF function of SOS1 (Freedman et al., Proc. Natl. Acad. Sci. US A., 2006, Vol. 103 (No. 45): pp. 16692-1667; Pierre et al., Biochem. Pharmacol., 2011, Vol. 82 (No. 9): pp. 1049-1056). Published data demonstrate the important involvement of SOS1 in mutant KRAS activation and oncogenic signaling in cancer (Jeng et al., Nat. Commun., 2012, Vol. 3: No. 1, p. 168). SOS1 depletion reduced the proliferation rate and survival of tumor cells with KRAS mutations, but no effect was observed in KRAS wild-type cell lines. Introducing a mutated catalytic site of SOS1 did not rescue the effects of SOS1 loss, demonstrating the essential role of SOS1 GEF activity in KRAS-mutated cancer cells.

[0005] SOS1 is critically involved in the activation of RAS family protein signaling in cancer through a mechanism other than mutation in RAS family proteins. SOS1 interacts with the adapter protein Grb2, and the resulting SOS1 / Grb2 complex binds to activated / phosphorylated receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A / B, FGFR1 / 2 / 3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3, AXL) (e.g., Pierre et al., Biochem.Pharmacol., 2011, Vol. 82 (No. 9): pp. 1049-1056). SOS1 is also recruited to other phosphorylated cell surface receptors, such as the T cell receptor (TCR), B cell receptor (BCR), and monocyte colony-stimulating factor receptor (Salojin et al., J. Biol. Chem. 2000, Vol. 275 (No. 8): pp. 5966-75). This localization of SOS1 to the plasma membrane in close proximity to RAS family proteins allows SOS1 to promote RAS family protein activation. SOS1 activation of RAS family proteins can also be mediated by SOS1 / Grb2 interactions with the BCR-ABL oncogeneic protein commonly found in chronic myeloid leukemia (Kardinal et al., 2001, Blood, Vol. 98: pp. 1773-81; Sini et al., Nat. Cell Biol. 2004, Vol. 6 (No. 3): pp. 268-74). Furthermore, alterations in SOS1 are associated with cancer. SOS1 mutations are found in embryonal rhabdomyosarcomas, testicular Sertoli cell tumors, cerebrospinal granulomas (Denayer et al., Genes Chromosomes Cancer, 2010, Vol. 49 (No. 3): pp. 242-52), and lung adenocarcinoma (Cancer Genome Atlas Research Network, Nature, 2014, Vol. 511 (No. 7511): pp. 543-50).On the other hand, SOS1 overexpression has been explained in bladder cancer (Watanabe et al., IUBMB Life., 2000, Vol. 49 (No. 4): pp. 317-320) and prostate cancer (Timofeeva et al., Int. J. Oncol., 2009, Vol. 35 (No. 4): pp. 751-760). In addition to cancer, hereditary SOS1 mutations are associated with the development of rasopathies such as Noonan syndrome (NS), cardio-facio-cutaneous syndrome (CFC), and hereditary gingival fibromatosis type 1 (Pierre et al., Biochem. Pharmacol., 2011, Vol. 82 (No. 9): pp. 1049-1056).

[0006] SOS1 is also a GEF for the activation of the GTPase RAC1 (Ras-related C3 botulinum toxin substrate 1) (Innocenti et al., J. Cell Biol., 2002, Vol. 156 (No. 1): pp. 125-136). RAC1, like other RAS family proteins, is involved in the development of various human cancers and other diseases (Bid et al., Mol. Cancer Ther., 2013, Vol. 12 (No. 10): pp. 1925-1934).

[0007] Son of Sevenless 2 (SOS2), a homolog of SOS1 in mammalian cells, also acts as a GEF for the activation of RAS family proteins (Pierre et al., Biochem. Pharmacol., 2011, Vol. 82 (No. 9): pp. 1049-1056; Buday et al., Biochim. Biophys. Acta., 2008, Vol. 1786 (No. 2): pp. 178-1787). Published data from mouse knockout models suggest a role for the excess of SOS1 and SOS2 in maintaining homeostasis in adult mice. Germline knockout of SOS1 in mice resulted in lethality during mid-embryonic gestation (Qian et al., EMBO J., 2000, Vol. 19 (No. 4): pp. 642-654), while systemic conditional SOS1 knockout adult mice were viable (Baltanas et al., Mol. Cell. Biol., 2013, Vol. 33 (No. 22): pp. 4562-4578). Targeting the SOS2 gene did not produce any clear phenotype in mice (Esteban et al., Mol. Cell. Biol., 2000, Vol. 20 (No. 17): pp. 6410-443). In contrast, double knockout of SOS1 and SOS2 resulted in rapid lethality in adult mice (Baltanas et al., Mol. Cell. Biol., 2013, Vol. 33 (No. 22): pp. 4562-4578). These published data suggest that selective targeting of individual SOS isoforms (e.g., selective SOS1 targeting) is adequately permissible to achieve therapeutic indexes between SOS1 / RAS family protein-driven cancers (or other SOS1 / RAS family protein-related pathologies) and normal cells and tissues.

[0008] Selective pharmacological inhibition of the binding of the SOS1 catalytic site to RAS family proteins is expected to prevent SOS1-mediated activation of RAS family proteins to their GTP-bound form. Such SOS1 inhibitor compounds are expected to consequently inhibit downstream cellular signaling (e.g., ERK phosphorylation) of RAS family proteins. In cancer cells associated with dependence on RAS family proteins (e.g., KRAS mutant cancer cell lines), SOS1 inhibitor compounds are expected to achieve anti-cancer efficacy (e.g., inhibition of proliferation, survival, metastasis, etc.). SOS1: RAS family protein binding (nanomolar level IC) 50 (value) and ERK phosphorylation in cells (nanomolar level IC) 50 High efficacy in inhibiting SOS1 is a desirable characteristic of SOS1 inhibitor compounds. Furthermore, a desirable characteristic of SOS1 inhibitor compounds would be selective inhibition of SOS1 compared to SOS2. This conclusion is based on the viable phenotype of SOS1 knockout mice and the lethality of SOS1 / SOS2 double knockout mice, as described above.

[0009] These characteristics are not adequately achieved with the SOS1 inhibitor compounds described earlier. Over the past few decades, RAS family protein-SOS1 protein interactions have become increasingly recognized. To date, several attempts to identify and optimize binders have targeted either the effector binding site of RAS or the catalytic binding site of SOS1 (see Lu et al., ChemMedChem. 2016, Vol. 11 (No. 8): pp. 814-821 for a selective review), but have been limited in success.

[0010] In recent years, small activating molecules have been identified that bind to the lipophilic pocket of SOS1 adjacent to the RAS binding site (Bums et al., Proc. Natl. Acad. Sci. 2014, Vol. 111 (No. 9): pp. 3401-3406). However, the binding of these molecules appears to increase nucleotide exchange, thereby activating the RAS instead of inactivating it.

[0011] In efforts to stabilize the protein-protein interaction between RAS family proteins and SOS1 and prevent the refilling of RAS family proteins with GTP, several different fragments were subsequently identified (Winter et al., J. Med. Chem. 2015, vol. 58(no. 5): pp. 2265-74). However, the reversible binding of the fragments to SOS1 did not translate into a measurable effect of nucleotide exchange, and only a weak effect was observed with fragments covalently bound to RAS.

[0012] Recently, research has also been conducted that combines rational design and screening platforms to identify small molecule inhibitors of SOS1, i.e., compounds that bind to SOS1 and inhibit protein-protein interactions with RAS family proteins (Evelyn et al., Chem. Biol. 2014, Vol. 21 (No. 12): pp. 1618-1628; Evelyn et al., J. Biol. Chem. 2015, Vol. 290 (No. 20): pp. 12879-12898; Zheng et al., WO2016 / 077793). Compounds with slight inhibitory effects on SOS1 have been identified, but their effects on guanine nucleotide exchange and regulation of cellular signaling (e.g., ERK phosphorylation) are weak. WO2018 / 115380 and WO2018 / 172250 disclose quinazoline-based SOS inhibitors.

[0013] Therefore, there is a need for novel compounds that modulate SOS1 activity for the treatment of diseases and disorders (e.g., neoplastic diseases). [Overview of the Initiative] [Means for solving the problem]

[0014] This disclosure provides SOS1 inhibitors, such as compounds of structural formulas (I), (II), (III-A), or (III-B), pharmaceutically acceptable salts thereof, stereoisomers, and pharmaceutical compositions. Surprisingly, the compounds disclosed herein have been found to significantly improve human liver microsome stability and effectively inhibit SOS1 activity.

[0015] [ka]

[0016] This disclosure further provides methods for using the compounds disclosed herein (e.g., compounds of structural formulas (I), (II), (III-A), or (III-B)), their pharmaceutically acceptable salts, stereoisomers, or pharmaceutical compositions to inhibit the activity of SOS1.

[0017] This disclosure further provides methods for using the compounds disclosed herein (e.g., compounds of structural formulas (I), (II), (III-A), or (III-B)), their pharmaceutically acceptable salts, stereoisomers, or pharmaceutical compositions for treating conditions, diseases, or disorders in which inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial, specifically in the treatment of neoplastic diseases.

[0018] In one embodiment, the present disclosure provides a compound of any one of the formulas described herein (e.g., structural formulas (I), (II), (III-A), or (III-B)), a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

[0019] In one embodiment, the present disclosure provides a pharmaceutical composition comprising, in a mixture having at least one pharmaceutically acceptable carrier, one compound of any of the formulas described herein (e.g., structural formulas (I), (II), (III-A), or (III-B)) as defined in any one of the embodiments described herein, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

[0020] In another aspect, the Disclosure provides a compound of any one of the formulas described herein (e.g., structural formulas (I), (II), (III-A), or (III-B)) as defined in any one of the embodiments described herein, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, for use as a pharmaceutical.

[0021] In another aspect, the Disclosure provides a compound of any one of the formulas described herein (e.g., structural formulas (I), (II), (III-A), or (III-B)), a pharmaceutically acceptable salt, or a stereoisomer thereof, as defined in any one of the embodiments described herein, for use in the treatment of conditions, diseases, or disorders in which inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial, specifically in the treatment of neoplastic diseases.

[0022] In another aspect, the Disclosure provides the use of any one compound of the formulas described herein (e.g., structural formulas (I), (II), (III-A), or (III-B)), a pharmaceutically acceptable salt or stereoisomer thereof, as defined in any one of the embodiments described herein, for the manufacture of a pharmaceutically acceptable compound in the treatment of neoplastic diseases, for the treatment of conditions, diseases, or disorders in which inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial. [Modes for carrying out the invention]

[0023] 1.Compound In the first embodiment, this disclosure relates to formula (I)

[0024] [ka]

[0025] Compounds represented by, their pharmaceutically acceptable salts or stereoisomers (wherein, Ring A is a 3- to 12-membered carbocyclic, 3- to 12-membered heterocyclic, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; R 1 is hydrogen, halogen, C 1~6 alkyl or C 3~6 cycloalkyl, and the C 1 alkyl or C 1~6 cycloalkyl represented by R 3~6 is optionally substituted by one or more groups selected from halogen and -OH; V is N or CR 2 ; R 2 is hydrogen, halogen, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, -OR 2a , -NR 2a R 2b , -C(O)R 2a , -C(O)OR 2a , -C(O)NR 2a R 2b , -SO2R 2a , -SO2NR 2a R 2b , -P(O)R 2a R 2b , -NR 2a C(O)R 2b , -NR 2a C(O)OR 2b , -NR 2a SO2R 2b , -NR 2a SO2NR 2b R 2c , a 3- to 12-membered carbocyclic, 3- to 12-membered heterocyclic, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; R 2 The C 1~6 alkyl, C 2~6 alkenyl, C 2~6 [[ID=7,8]]alkynyl, 3- to 12-membered carbocyclic, 3- to 12-membered heterocyclic, 6- to 10-membered aryl or 5- to 10-membered heteroaryl represented by R 2d is optionally substituted by one or more R R 2a , R 2b and R 2c These are, independently, hydrogen and C 1~6 Selected from the group consisting of alkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R 2a and R 2b Or R 2b and R 2c They, together with the N or P atom to which they bond, form a 4-12 member heterocycline or a 5-10 member heteroaryl; R 2a , R 2b Or R 2c Represented by or R 2a , R 2b Or R 2c The C in the base represented by 1~6 Alkyl, carbocyrill, heterocyclyl, aryl, or heteroaryl may be used as one or more R as needed. 2d Replaced by; R 2d In each appearance, hydrogen, halogen, oxo, -CN, and C are present. 1~6 Alkyl, C 1~6 Haloalkyl, -OR 2e , -NR 2e R 2f , -C(O)R 2e , -C(O)OR 2e -C(O)NR 2e R 2f , -SO2R 2e -SO2NR 2e R 2f ,-P(O)R 2e R 2f , -NR 2e C(O)R 2f , -NR 2e C(O)OR 2f , -NR 2e SO2R 2f , -NR 2e SO2NR 2f R 2g These are 3-12 membered carbocyclyls, 3-12 membered heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls; R 2e 、R 2f and R 2g are each independently selected from the group consisting of hydrogen and C 1~6 alkyl; X is N or CR 3 ; R 3 is hydrogen, halogen or C 1~3 alkyl; R 4 is hydrogen or C 1~6 alkyl; R 5 is hydrogen, C 1~6 alkyl, a 3- to 6-membered monocyclic carbocyclic, or a 4- to 6-membered monocyclic heterocyclic; the C 5 alkyl, 3- to 6-membered monocyclic carbocyclic or 4- to 6-membered monocyclic heterocyclic represented by R 1~6 is optionally substituted with one or more groups selected from halogen and -OH; R 6 is hydrogen, -OH, halogen, -CN, oxo, C 1~6 alkyl, C 1~6 alkoxy, -SO2R 6a , -SO2NR 6a R 6b , -P(O)R 6a R 6b , -C(O)NR 6a R 6b , -NR 6a C(O)R 6a , -NR 6a C(O)NR 6a R 6b , -(CH2) s NR 6a R 6b , -O(CH2) t NR 6a R 6b , a 3- to 12-membered carbocyclic, a 3- to 12-membered heterocyclic, a 6- to 10-membered aryl, a 5- to 10-membered heteroaryl; the C 6 alkyl, C 1~6 alkyl, C 1~6Alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl may have one or more R 6c It is sometimes replaced by; R 6a and R 6b These are independently hydrogen or C 1~6 Alkyl or R 6a and R 6b These, together with the N or P atom to which they are bonded, form a 4-7 member heterocycline; s is an integer between 0 and 3; t is an integer between 2 and 4; R 6c Each instance is represented by hydrogen, -OH, halogen, -CN, oxo, and C. 1~6 Alkyl, C 1~6 Alkoxy, C 3~6 Cycloalkyl, -NR 6a R 6b , -SO2R 6a -SO2NR 6a R 6b -C(O)NR 6a R 6b ,-P(O)R 6a R 6b , -NR 6a C(O)R 6a , -NR 6a C(O)NR 6a R 6b ,-(CH2) s NR 6a R 6b or -O(CH2) t NR 6a R 6b And; R 6c The C represented by 1~6 Alkyl or C 3~6 Cycloalkyls include halogens, -OH and -NR 6a R 6b It is optionally substituted with one or more elements selected from; R 7 and R 8 Hydrogen and C are independent of each other. 1~6 Alkyl, C 3~6 Alkenil, C3~6 Alkinyl, C 2~6 These are alkoxys, 3-12 membered carbocyclyls, 3-12 membered heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls; R 7 Or R 8 The C represented by 1~6 Alkyl, C 3~6 Alkenil, C 3~6 Alkinyl, C 2~6 Alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl may have one or more R 7a It may be replaced by, or R 7 and R 8 These, together with the N atom to which they are bonded, form a 4-12 member heterocyclil or a 5-10 member heteroaryl; and the 4-12 member heterocyclil or 5-10 member heteroaryl consists of one or more R 7b It is sometimes replaced by this; R 7a Hydrogen, halogen, -CN, C 1~6 Alkyl, -OR 7c , -NR 7c R 7d , -C(O)R 7c , -C(O)OR 7c -C(O)NR 7c R 7d , -SO2R 7c ,-P(O)R 7c R 7d -SO2NR 7c R 7d , -NR 7c C(O)R 7d , -NR 7c C(O)OR 7d , -NR 7c SO2R 7d , -NR 7c SO2NR 7d R 7e , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl or 5-10 membered heteroaryl, R 7a The C represented by1~6 Alkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl may be one or more R 7f It is sometimes replaced by; R 7b These are hydrogen, halogen, -CN, oxo, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 1~6 Alkoxy, -OR 7c , -NR 7c R 7d , -C(O)R 7c , -C(O)OR 7c -C(O)NR 7c R 7d , -SO2R 7c ,-P(O)R 7c R 7d -SO2NR 7c R 7d , -NR 7c C(O)R 7d , -NR 7c C(O)OR 7d , -NR 7c SO2R 7d , -NR 7c SO2NR 7d R 7e , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl or 5-10 membered heteroaryl, R 7b C represented by 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 1~6 Alkoxy, 3-12 membered carbocyryl, 3-12 membered heterocyclyl, or 5-10 membered heteroaryl may be one or more R 7f It is sometimes replaced by; R 7c , R 7d and R 7e Hydrogen and C are independent of each other. 1~6 Selected from the group consisting of alkyl, 3-12 membered carbocyclyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R7c and R 7d These, together with the N or P atom to which they are bonded, form 4-12 member heterocyclines or 5-10 member heteroaryls; R 7c , R 7d Or R 7e Represented by or R 7c , R 7d Or R 7e The C in the base represented by 1~6 Alkyl, carbocyrill, heterocyclyl, aryl, or heteroaryl is one or more R 7f It is sometimes replaced by; R 7f In each occurrence, it is hydrogen, halogen, -CN, or OH; n is 0, 1, 2, or 3; The heterocyclyl comprises 1 to 4 heteroatoms selected from O, N, and S; the heteroaryl comprises 1 to 4 heteroatoms selected from O, N, and S. To provide.

[0026] In a second embodiment, the present disclosure relates to a compound according to the first embodiment, wherein formula II

[0027] [ka]

[0028] The compound represented by, its pharmaceutically acceptable salts or stereoisomers are provided, and the definitions of the variables are provided in the first embodiment. In the third embodiment, the disclosure relates to the compounds according to the first and second embodiments, their pharmaceutically acceptable salts, or stereoisomers. (In the formula, Ring A is a 3-10 membered carbocyclyl, a 4-10 membered heterocyclyl, a 6-10 membered aryl, or a 5-10 membered heteroaryl; R 1 is hydrogen, C 1~4 Alkyl or C 3~6 It is a cycloalkyl; R 2 Hydrogen, halogen, -CN, C 1~4 Alkyl, C 2~4 Alkenil, C 2~4 Alkinyl, -OR 2a , -NR 2a R 2b , -C(O)R 2a , -C(O)OR 2a -C(O)NR 2a R 2b , -NR 2a C(O)R 2b , -NR 2a C(O)OR 2b , 3-6 member monocyclic carbocyrills, 3-6 member monocyclic heterocyclines, 6-10 member aryls, or 5-10 member heteroaryls; R 2 The C represented by 1~4 Alkyl, C 2~4 Alkenil, C 2~4 Alkinyls, 3-6 membered monocyclic carbocyclyls, 3-6 membered monocyclic heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls have 1-3 R 2d It is sometimes replaced by; R 2a and R 2b These are, independently, hydrogen and C 1~6 Alkyl, C 1~6 Haloalkyl or C 1~6 Selected from the group consisting of hydroxyalkyl groups; or R 2a and R 2b These, together with the N atom to which they are bonded, form 4-12 member heterocyclines or 5-10 member heteroaryls; R 2d In each appearance, hydrogen, halogen, oxo, -CN, and C are present. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, -OR 2e , -NR 2e R 2f , -SO2R 2e ,-P(O)R 2e R 2f COOR 2e CONR 2eR 2f These are 3-6 member monocyclic carbocyclyls, 3-6 member monocyclic heterocyclyls, 6-10 member aryls, or 5-10 member heteroaryls; R 2e and R 2f Hydrogen and C are independent of each other. 1~6 Selected from the group consisting of alkyl groups; R 5 is hydrogen, C 1~4 Alkyl, 3-5 membered monocyclic carbocyrill, or 4-5 membered monocyclic heterocyclyl; R 6 These are hydrogen, -OH, halogen, -CN, oxo, and C. 1~6 Alkyl, -(CH2) s NR 6a R 6b These are 3-6 member monocyclic carbocyclyls, 3-6 member monocyclic heterocyclyls, 6-10 member aryls, and 5-10 member heteroaryls; R 6 The C represented by 1~6 Alkyl, 3-6 membered monocyclic carbocyryl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl may be used as one or more R as needed. 6c Replaced by; R 6a and R 6b These are independently hydrogen or C 1~4 It is alkyl; s is an integer between 0 and 2; R 6c Each instance is represented by hydrogen, -OH, halogen, -CN, oxo, and C. 1~6 Alkyl, -NR 6a R 6b or -(CH2) s NR 6a R 6b And; R 6c The C represented by 1~6 Alkyl groups are optionally substituted with one or more groups selected from halogens and -OH groups; R 7 and R 8 Hydrogen and C are independent of each other. 1~4 Alkyl, C 3~4 Alkenil, C3~4 Alkinyl, C 2~4 The compounds are alkoxys, 3-6 membered monocyclic carbocyrills, 3-6 membered monocyclic heterocyclines, 6-10 membered aryls, or 5-10 membered heteroaryls; R 7 Or R 8 The C represented by 1~4 Alkyl, C 3~4 Alkenil, C 3~4 Alkinyl, C 2~4 Alkoxy, 3-6 membered monocyclic carbocyrills, 3-6 membered monocyclic heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls may have one or more R 7a It may be replaced by this depending on the circumstances; or R 7 and R 8 These, together with the N atom to which they are bonded, form a 4-12 member heterocyclil or a 5-10 member heteroaryl; the 4-12 member heterocyclil or 5-10 member heteroaryl may have 1-3 R 7b It is sometimes replaced by this; R 7a Hydrogen, halogen, -CN, C 1~6 Alkyl, -OR 7c , or -NR 7c R 7d and; R 7b These are hydrogen, halogen, -CN, oxo, and C. 1~6 Alkyl, C 1~6 Alkoxy, -OR 7c , -NR 7c R 7d , -C(O)R 7c , -C(O)OR 7c , -SO2R 7c Or a 5-10 member heteroaryl, R 7b C represented by 1~6 Alkyl, C 1~6 Alkoxy or 5-10 membered heteroaryls, one or more R 7f It is sometimes replaced by; R 7c Or R 7d Hydrogen and C are independent of each other. 1~4Selected from the group consisting of alkyls, 3-6 membered monocyclic carbocyclyls, 4-8 membered heterocyclyls, 6-10 membered aryls, and 5-10 membered heteroaryls; or R 7c and R 7d These, together with the N atom to which they are bonded, form a 4-8 member heterocycline or a 5-10 member heteroaryl; R 7c or R 7d The C represented by 1~4 Alkyls, 3-6 membered monocyclic carbocyryls, 4-8 membered heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls have 1-3 R 7f It is sometimes replaced by this; R 7f (Each occurrence is hydrogen, halogen, -CN, or OH.) To provide.

[0029] In the fourth embodiment, the disclosure relates to a compound according to any one of the first to third embodiments, its pharmaceutically acceptable salt or stereoisomer. (In the formula, R 2 Hydrogen, halogen, -CN, C 1~4 Alkyl, C 2~4 Alkenil, C 2~4 Alkinyl, 3-6 member monocyclic carbocyclyl, 3-6 member monocyclic heterocyclyl, 6-10 member aryl, or 5-10 member heteroaryl; R 2 The C represented by 1~4 Alkyl, C 2~4 Alkenil, C 2~4 Alkinyls, 3-6 membered monocyclic carbocyclyls, 3-6 membered monocyclic heterocyclyls, 6-10 membered aryls, or 5-10 membered heteroaryls have 1-3 R 2d It is sometimes replaced by; R 2d In each appearance, hydrogen, halogen, oxo, -CN, and C are present. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, -OR 2e , -NR 2e R 2f, -SO2R 2e ,-P(O)R 2e R 2f COOR 2e CONR 2e R 2f These are 3-6 member monocyclic carbocyclyls, 3-6 member monocyclic heterocyclyls, 6-10 member aryls, or 5-10 member heteroaryls; R 2e and R 2f Hydrogen and C are independent of each other. 1~6 (Selected from the group consisting of alkyl groups) To provide.

[0030] In the fifth embodiment, the disclosure relates to a compound according to any one of the first to fourth embodiments, its pharmaceutically acceptable salt, or stereoisomer. (In the formula, R 7 and R 8 Hydrogen and C are independent of each other. 1~4 Alkyl, C 3~4 Alkenil, C 3~4 It is alkinyl; R 7 Or R 8 The C represented by 1~4 Alkyl, C 3~4 Alkenil, C 3~4 Alkinyl is one or more R 7a It may be replaced by this depending on the circumstances; or R 7 and R 8 These, together with the N atom to which they are bonded, form a 4-12 member heterocyclyl or a 5 member heteroaryl, each containing 1-3 R atoms. 7b It is sometimes replaced by this; R 7a Hydrogen, halogen, -CN, C 1~6 Alkyl, -OR 7c , or -NR 7c R 7d and; R 7b These are hydrogen, halogen, -CN, oxo, -OH, C 1~6 Alkyl, C 1~6 Alkoxy, -NR 7c R7d , -C(O)R 7c , -C(O)OR 7c , -SO2R 7c Or a 5-10 member heteroaryl, R 7b C represented by 1~6 Alkyl, C 1~6 Alkoxy or 5-10 membered heteroaryls, one or more R 7f It is sometimes replaced by; R 7c Or R 7d Hydrogen and C are independent of each other. 1~4 Selected from the group consisting of alkyls, 3-6 membered monocyclic carbocyclyls, 4-8 membered heterocyclyls, 6-10 membered aryls, and 5-10 membered heteroaryls; or R 7c and R 7d These, together with the N atom to which they are bonded, form a 4-8 member heterocycline or a 5-10 member heteroaryl; R 7c or R 7d The C represented by 1~4 Alkyl, 3-6 membered carbocyclyl, 4-8 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl may have 1-3 R 7f It is sometimes replaced by this; R 7f (Each occurrence is hydrogen, halogen, -CN, or OH.) To provide.

[0031] In the sixth embodiment, the disclosure relates to the compounds according to the first, second, third, fourth, or fifth embodiments, their pharmaceutically acceptable salts, or stereoisomers. (In the formula, Ring A is a 3-6 member monocyclic cycloalkyl, a 4-6 member monocyclic heterocyclyl, a phenyl, or a 5-10 member heteroaryl; R 6 These are hydrogen, -OH, halogen, -CN, and C 1~6 Alkyl or -(CH2) s NR 6a R 6b And; R 6 The C represented by 1~6Alkyl groups are optionally substituted with one or more groups selected from halogens and -OH groups; R 6a and R 6b These are independently hydrogen or C 1~4 It is alkyl; (s is either 0 or 1) To provide.

[0032] In the seventh embodiment, the disclosure relates to a compound according to the first, second, third, fourth, fifth, or sixth embodiment, a pharmaceutically acceptable salt thereof, or a stereoisomer (wherein ring A is cyclopropyl, phenyl, thiophenyl, or indole). To provide.

[0033] In the eighth embodiment, the disclosure provides a compound according to the first, second, third, fourth, fifth, sixth, or seventh embodiment, a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is of formula (III-A) or (III-B)

[0034] [ka]

[0035] It is represented by [this]. The definition of the variables is provided in any one of the first to seventh embodiments. In the ninth embodiment, the disclosure relates to a compound according to the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment, a pharmaceutically acceptable salt or stereoisomer thereof (wherein R 6 is hydrogen, halogen, C 1~4 Alkyl or -(CH2)NR 6a R 6b And; R 6 The C represented by 1~4 Alkyl groups are optionally substituted with one or more groups selected from halogens and -OH groups; R 6a and R 6b These are independently hydrogen or C 1~4 (It is alkyl.) To provide.

[0036] In the tenth embodiment, the disclosure relates to a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, a pharmaceutically acceptable salt or stereoisomer thereof (wherein R 5 It provides hydrogen, methyl, or ethyl (methyl if necessary).

[0037] In the eleventh embodiment, the disclosure relates to compounds according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth or tenth embodiment, their pharmaceutically acceptable salts or stereoisomers. (In the formula, R 2 Hydrogen, halogen, -CN, C 1~4 Alkyl, C 2~4 Alkenyl, 3-6 member monocyclic cycloalkyl, 5-6 member monocyclic heterocyclyl, phenyl, or 5-10 member heteroaryl; R 2 The C represented by 1~4 Alkyl, 3-6 membered monocyclic cycloalkyl, 5-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl may have 1-3 R 2d It is sometimes replaced by; R 2d In each appearance, hydrogen, halogen, oxo, -CN, and C are present. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, -OR 2e , -NR 2e R 2f , -SO2R 2e ,-P(O)R 2e R 2f COOR 2e CONR 2e R 2f These are 3-6 member monocyclic carbocyclyls, 3-6 member monocyclic heterocyclyls, phenyls, or 5-10 member heteroaryls; R 2e and R 2f Hydrogen and C are independent of each other. 1~6 (Selected from the group consisting of alkyl groups) To provide.

[0038] In the twelfth embodiment, the disclosure relates to compounds according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment, their pharmaceutically acceptable salts or stereoisomers. (In the formula, R 2 is phenyl or a 5-10 member heteroaryl; the phenyl or 5-10 member heteroaryl has 1-3 R 2d It is sometimes replaced by; R 2d In each appearance, hydrogen, halogen, -CN, and C are present. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, -OR 2e , -NR 2e R 2f , -SO2R 2e ,-P(O)R 2e R 2f COOR 2e CONR 2e R 2f These are 3-6 member monocyclic carbocyclyls, 3-6 member monocyclic heterocyclyls, phenyls, or 5-10 member heteroaryls; R 2e and R 2f Hydrogen and C are independent of each other. 1~6 (Selected from the group consisting of alkyl groups) To provide.

[0039] In the 13th embodiment, the disclosure relates to a compound according to the 12th embodiment, its pharmaceutically acceptable salt or stereoisomer (wherein R 2 These are phenyl, pyridyl, pyrimidyl, imidazolyl, pyrazolyl, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyridine, or triazolo[4,3-a]pyridine, each containing 1 to 3 R 2d It is sometimes replaced by R; 2d (Selected from the group consisting of hydrogen, halogen, -CN, -CH3, -CF3, -NH2, -S(O)2Me, -OCH3, COOH, CONH2, COOMe, -P(O)(CH3)2, -CH2CH2OH, and -CH2CHF2) To provide.

[0040] In the 14th embodiment, the disclosure relates to a compound according to the 13th embodiment, its pharmaceutically acceptable salt or stereoisomer (wherein R 2 It is phenyl or pyridyl; each of them has 1 to 3 R 2d It is sometimes replaced by R; 2d This provides hydrogen, halogen, -CN, -CH3, -CF3, -NH2, -S(O)2Me, -OCH3, COOH, CONH2, COOMe, -P(O)(CH3)2, -CH2CH2OH, and -CH2CHF2 (selected from the group).

[0041] In the 15th embodiment, the disclosure relates to a compound according to the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th or 14th embodiment, its pharmaceutically acceptable salt or stereoisomer (wherein R 7 and R 8 These, together with the N atom to which they are bonded, form 5-10 membered heterocyclyls or 5 membered heteroaryls, each of which is a halogen, -CN, oxo, -OH, or C. 1~6 Alkyl, C 1~6 Alkoxy, -C(O)R 7c , -C(O)OR 7c and optionally substituted with 1 to 3 pyridinyl groups selected from those substituted with CN; R 7c The carbon atoms are independently substituted with hydrogen, and optionally with -CN or -OH. 1~4 (Selected from the group consisting of alkyl groups) To provide.

[0042] In the sixteenth embodiment, the disclosure relates to a compound according to the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, or fourteenth embodiment, its pharmaceutically acceptable salt or stereoisomer (wherein R 7 and R 8 These are independently hydrogen or C 1~4It is alkyl, and R as needed. 7 and R 8 It provides (which is methyl).

[0043] In the 17th embodiment, the disclosure relates to the compounds according to the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 15th or 16th embodiments, their pharmaceutically acceptable salts or stereoisomers. (In the formula, R 2 H, F, Br, CH3, -CN,

[0044] [ka]

[0045] Selected from the group consisting of, R 2d (Selected from the group consisting of hydrogen, halogen, -CN, -CH3, -CF3, -NH2, -S(O)2Me, -OCH3, COOH, CONH2, COOMe, -P(O)(CH3)2, -CH2CH2OH, and -CH2CHF2) To provide.

[0046] In the 18th embodiment, the disclosure relates to a compound according to the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th or 17th embodiment, a pharmaceutically acceptable salt or stereoisomer thereof (wherein R 7 and R 8 They, together with the atoms to which they are bonded,

[0047] [ka]

[0048] A heterocycline is formed by selecting from the group consisting of the following: Each of these is -F, -CN, oxo, -OH, methyl, isopropyl, methoxyl, -C(O)R 7c , -C(O)OR 7c(and optionally substituted with 1 to 3 groups selected from pyridinyl groups that are substituted with CN) To provide.

[0049] In one embodiment, the present disclosure provides compounds selected from the compounds disclosed in the Examples and Table 1, their pharmaceutically acceptable salts, or stereoisomers.

[0050] [Table 1-1]

[0051] [Table 1-2]

[0052] [Table 1-3]

[0053] [Table 1-4]

[0054] [Table 1-5]

[0055] [Table 1-6]

[0056] [Table 1-7]

[0057] [Table 1-8]

[0058] Table 1-9

[0059] Table 1-10

[0060] Table 1-11

[0061] Table 1-12

[0062] Table 1-13

[0063] Table 1-14

[0064] Table 1-15

[0065] Table 1-16

[0066] Table 1-17

[0067] Table 1-18

[0068] Table 1-19

[0069]

Table 1-20

[0070]

Table 1-21

[0071]

Table 1-22

[0072]

Table 1-23

[0073]

Table 1-24

[0074] 2. Definitions As used herein, the term "halogen" refers to fluoride, chloride, bromide or iodide.

[0075] The term "alkyl", used alone or as part of a larger moiety, such as "alkoxy" or "haloalkyl", means a saturated aliphatic straight or branched chain monovalent hydrocarbon group of the formula -C n H (2n+1) Unless otherwise specified, an alkyl group typically has 1 to 6 carbon atoms, i.e., C 1~6 alkyl. As used herein, the term "C 1~6 alkyl" group means a group having 1 to 6 carbon atoms in a straight or branched chain configuration. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, hexyl, and the like.

[0076] When used herein, the term "alkylene" refers to a linear or branched chain of alkylenes of formula C n H 2n It refers to a divalent hydrocarbon group. Non-restrictive examples include ethylene and propylene.

[0077] The term "alkenyl" refers to an alkyl group in which one or more carbon / carbon single bonds are replaced by double bonds. The term "alkynyl" refers to an alkyl group in which one or more carbon / carbon single bonds are replaced by triple bonds.

[0078] The term "alkoxy" refers to an alkyl group bonded through an oxygen-bonding atom, and is represented as -O-alkyl. Examples of "(C1-C4) alkoxy" include methoxy, ethoxy, propoxy, and butoxy.

[0079] The term "haloalkyl" refers, in some cases, to an alkyl group that is substituted with one or more halogen atoms. The term "hydroxyalkyl" sometimes refers to an alkyl group that is substituted with one or more hydroxyl groups.

[0080] The term "carbocyclyl" refers to any stable, non-aromatic hydrocarbon ring having 3 to 12 membered carbocyclyls. In one embodiment, a carbocyclyl is a monocyclic or dicyclic hydrocarbon ring with 3, 4, 5, 6, 7, or 8 membered, or a dicyclic or tricyclic hydrocarbon ring with 7, 8, 9, 10, 11, or 12 membered, any of which may be saturated, partially unsaturated, or unsaturated. Any substitutable ring atom can be substituted (e.g., by one or more substituents). Examples of such carbocyclyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl. In one embodiment, carbocyclyls are intended to include bridged, condensed, and spirocyclic rings. In spirocyclic carbocyclyls, one atom is common to two different rings. An example of a spirocyclic carbocyclyl is spiropentanyl. In bridging carbocyclyls, the rings share at least two common non-adjacent atoms. Examples of bridging carbocyclyls include bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hepta-2-enyl, and adamantanyl. In fused carbocyclyl systems, two or more rings can be fused together such that two rings share one common bond. Examples of two or three fused carbocyclyls include naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenantrenyl, and dekalinyl.

[0081] The term "cycloalkyl" refers to a cyclic, dicyclic, tricyclic, or polycyclic saturated hydrocarbon group having 3 to 12 cyclic carbon atoms. In one embodiment, a cycloalkyl group may have 3 to 7 cyclic carbon atoms. Any substitutable ring atom can be substituted (e.g., by one or more substituents). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. A cycloalkyl group may contain multiple condensed and / or crosslinked rings. Non-limiting examples of condensed / crosslinked cycloalkyls include bicyclo[1.1.0]butane, bicyclo[2.1.0]pentane, bicyclo[1.1.0]pentane, bicyclo[3.1.0]hexane, bicyclo[2.1.1]hexane, bicyclo[3.2.0]heptane, bicyclo[4.1.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[4.2.0]octane, bicyclo[3.2.1]octane, and bicyclo[2.2.2]octane. Cycloalkyls also include spirocyclic rings (for example, spirocyclic bicycles in which two rings are bonded through only one atom). Non-limiting examples of spirocyclic cycloalkyls include spiro[2.2]pentane, spiro[2.5]octane, spiro[3.5]nonane, spiro[3.5]nonane, spiro[4.4]nonane, spiro[2.6]nonane, spiro[4.5]decane, spiro[3.6]decane, and spiro[5.5]undecane.

[0082] The term “heterocyclyl” or “heterocyclic” refers to a 3- to 12-membered non-aromatic ring system group ("3- to 12-membered heterocyclyl") having a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, quaternary nitrogen, nitrogen oxides (e.g., NO), oxygen, and sulfur, including sulfoxides and sulfones. In some embodiments, the heterocyclyl group is a 3- to 7-membered non-aromatic ring system ("3- to 7-membered heterocyclyl") having a ring carbon atom and 1 to 4 ring heteroatoms, each heteroatom independently selected from nitrogen, oxygen, and sulfur. In heterocyclyl groups containing one or more nitrogen atoms, the attachment site can be a carbon or nitrogen atom, where valence is acceptable. A heterocyclyl group can be monocyclic ("monocyclic heterocyclyl") or polycyclic (e.g., bicyclic ("bicyclic heterocyclyl") or tricyclic ("tricyclic heterocyclyl"), with polycyclic systems including condensed, cross-linked, or spirocyclic systems). Exemplary monocyclic heterocyclyl groups include azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, azepanyl, oxepanyl, thiepanyl, and tetrahydropyridinyl. A heterocyclyl polycyclic system may contain heteroatoms in one or more rings within the polycyclic system. Substituents may be present in one or more rings within the polycyclic system.

[0083] A spiroheterocyclyl refers to a 5- to 12-membered polycyclic heterocyclyl having rings bonded through a single common carbon atom (called a spiro atom), where the rings have one or more heteroatoms selected from the group consisting of nitrogen, quaternary nitrogen, nitric oxide (e.g., NO), oxygen, and sulfur including sulfoxides and sulfones, the remaining ring atoms are carbon, and one or more rings may contain one or more double bonds, but none of the rings have a fully conjugated π-electron system. Typical examples of spiroheterocyclyls include, but are not limited to, the following groups:

[0084] [ka]

[0085] These are some examples. A condensed heterocyclyl refers to a 5-12 membered polycyclic heterocyclyl group, where each ring in the group shares a pair of adjacent carbon atoms with another ring in the group, and one or more rings may contain one or more double bonds, but at least one of the rings does not have a fully conjugated π-electron system, and the ring has one or more heteroatoms selected from the group consisting of nitrogen, quaternary nitrogen, nitrogen oxides (e.g., NO), oxygen, and sulfur including sulfoxides and sulfones, and the remaining ring atoms are carbon. Typical examples of condensed heterocyclyls include, but are not limited to, the following groups:

[0086] [ka]

[0087] These are some examples. A bridging heterocyclyl refers to a 5-12 membered polycyclic heterocyclyl group, where any two rings in the group share two unbonded atoms, and the rings may have one or more double bonds but do not have a fully conjugated π-electron system. The rings have one or more heteroatoms as ring atoms selected from the group consisting of nitrogen, quaternary nitrogen, nitrogen oxides (e.g., NO), oxygen, and sulfur including sulfoxides and sulfones, and the remaining ring atoms are carbon. Typical examples of bridging heterocyclyls include, but are not limited to, the following groups:

[0088] [ka]

[0089] These are some examples. Generally, carbocyclyls, cycloalkyls, or heterocyclyls may be substituted or not substituted, but may be substituted with one or more substituents if the valence is permitted, and the substituents can be independently selected from several groups, such as oxo, -CN, halogen, alkyl, and alkoxyl, and alkyl substitutions may be further substituted as needed.

[0090] The term "aryl" refers to a monocyclic ring group or a polycyclic fused ring group (where "fused" means that each ring in the system shares pairs of adjacent carbon atoms with other rings in the system) with 6 to 10 members, all of which are carbon atoms, and which have a fully conjugated π-electron system. Typical examples of aryls are phenyl and naphthyl.

[0091] As used herein, the term "heteroaryl" refers to a monocyclic or polycyclic aromatic hydrocarbon in which at least one of the ring carbon atoms is independently substituted with a heteroatom selected from oxygen, nitrogen, and sulfur. Preferably, the heteroaryl is C 5~10 A heteroaryl group is based on an aryl group, in which one or more of its ring carbon atoms are substituted with a heteroatom. The heteroaryl group can be bonded through the ring carbon atoms or, if valence is permitted, through the ring nitrogen atom. Generally, heteroaryls may be unsubstituted or substituted with one or more substituents if valence is permitted, and the substituents are independently selected from halogens, OH, alkyl, alkoxyl, and amino (e.g., NH2, NHalkyl, N(alkyl)2), with alkyl groups being further substituted as needed.

[0092] As used herein, the term “treat” includes any effect that results in improvement of a condition, disease, disorder, etc., or improvement of their symptoms, such as reduction, decrease, regulation, improvement, or disappearance.

[0093] The term “therapeutic dose” refers to the amount of an agent (e.g., a compound described herein) that is effective in treating at least one symptom of a disease or disorder in a patient or subject. The “therapeutic dose” of an agent for administration may vary based on the desired activity, the condition of the patient or subject being treated, the dosage form, the method of administration, patient factors such as the patient’s sex, genotype, weight and age, the underlying cause of the condition or disease being treated, the route of administration and bioavailability, the persistence of the agent in the body, the evidence for natriuresis and / or diuresis, the type of formulation, and the potency of the agent. Pharmaceutically acceptable salts The term "pharmaceutically acceptable salt" refers to a pharmaceutical salt that, within the bounds of fair medical judgment, is appropriate for use in contact with human and lower animal tissues without unnecessary toxicity, irritation, or allergic reactions, and that offers a reasonable benefit-risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al. describe pharmacologically acceptable salts in J. Pharm. Sci., 1977, Vol. 66, pp. 1-19.

[0094] pharmaceutically acceptable salts of any one of the compounds in the above formulas include acid addition salts and base salts. The teaching also includes pharmaceutically acceptable salts of the compounds disclosed herein. Compounds having a basic group can form pharmaceutically acceptable salts with a pharmaceutically acceptable acid. Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include salts of inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, and sulfuric acid) and organic acids (e.g., acetic acid, benzenesulfonic acid, benzoic acid, ethanesulfonic acid, methanesulfonic acid, and succinic acid). Compounds of this teaching having an acidic group, such as a carboxylic acid, can form pharmaceutically acceptable salts with a pharmaceutically acceptable base. Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (e.g., sodium and potassium salts), and alkaline earth metal salts (e.g., magnesium and calcium salts).

[0095] A pharmaceutically acceptable salt of any one of the compounds in the above formula can be found in three ways: (i) Reacting one of the compounds from the above formulas with a desired acid or base. (ii) Removing an acid- or base-unstable protecting group from a suitable precursor of any one of the compounds of the above formulas, or opening a suitable cyclic precursor, such as a lactone or lactam, using the desired acid or base, (iii) Converting one salt of any one of the compounds in the above formulas to another by a reaction using an appropriate acid or base or by using an appropriate ion exchange column. It can be prepared using one or more of the following:

[0096] All three reactions typically occur in solution. The resulting salt can be precipitated and filtered off, or recovered by evaporation of the solvent. The degree of ionization in the resulting salt can vary from complete ionization to near-nonionization.

[0097] Any one of the compounds of the above formulas and its pharmaceutically acceptable salts may exist in non-solvated and solvated forms. Stereoisomers and other variations Any one of the compounds of the above formulas may exhibit one or more types of isomers (e.g., optical isomers, geometric isomers, or tautomers). Such variations are implied to any one of the compounds of the above formulas, defined by reference to the structural features of the compound, and are therefore within the scope of this disclosure.

[0098] Compounds containing one or more chiral centers can exist in various stereoisomeric forms; that is, each chiral center can have an R or S configuration, or a mixture of both. Stereoisomers are compounds that differ only in their spatial configuration. Stereoisomers include all diastereomers and enantiomers of a compound. Enantiomers are stereoisomers that are mirror images of each other. Diastereomers are stereoisomers that have two or more chiral centers that are not identical and are not mirror images of each other.

[0099] When a compound is named by its chemical name indicating a single enantiomer (e.g., when its configuration is indicated by a chemical name with "R" or "S") or by its structure (e.g., when its configuration is indicated by a "wedge-shaped" bond), unless otherwise indicated, the compound is optically pure (also called "enantiomerically pure") by at least 60%, 70%, 80%, 90%, 99%, or 99.9%. Optical purity is calculated by dividing the weight of the mixture of the named or depicted enantiomers by the total weight of the mixture of both enantiomers.

[0100] When the stereochemistry of a disclosed compound is named or depicted by structure, and when the named or depicted structure encompasses two or more stereoisomers (e.g., as a diastereomer pair), it is understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers is included. It is further understood that the stereoisomeric purity of the named or depicted stereoisomer is at least 60% by weight, 70% by weight, 80% by weight, 90% by weight, 99% by weight, or 99.9% by weight. In this case, the stereoisomeric purity is determined by dividing the total weight of the mixture of stereoisomers encompassed by name or structure by the total weight of the mixture of all stereoisomers.

[0101] When two stereoisomers are described by their chemical names or structures, and these chemical names or structures are connected by "and", a mixture of the two stereoisomers is intended. When two stereoisomers are described by these chemical names or structures, and the names or structures are connected by "or", one or the other of the two stereoisomers is intended, but not both.

[0102] When a disclosed compound having a chiral center is described by structure without indicating the stereochemistry at that chiral center, the structure means that it encompasses compounds having an S configuration at that chiral center, compounds having an R configuration at that chiral center, or compounds having a mixture of R and S configurations at that chiral center. When a disclosed compound having a chiral center is described by its chemical name without indicating the stereochemistry at that chiral center with "S" or "R", the name means that it encompasses compounds having an S configuration at that chiral center, compounds having an R configuration at that chiral center, or compounds having a mixture of R and S configurations at that chiral center.

[0103] A racemic mixture means that 50% is one enantiomer and 50% is its corresponding enantiomer. When a compound with one chiral center is named or drawn without representing the stereochemistry of the chiral center, it is understood that the name or structure encompasses both possible enantiomer forms of the compound (e.g., enantiomerically pure, enantiomerically-enriched, or racemic). When a compound with two or more chiral centers is named or drawn without representing the stereochemistry of the chiral center, it is understood that the name or structure encompasses all possible diastereomer forms of the compound (e.g., diastereomerically pure, diastereomer-enriched, or an equimolar mixture of one or more diastereomers (e.g., racemic)).

[0104] The term "geometric isomer" refers to a compound having at least one double bond, which can exist in cis (also called syn or entgegen (E)) or trans (also called anti or zusammen (Z)) form, or in mixtures thereof.

[0105] When structural isomers can be interconverted over low energy barriers, tautomeric isomerism ("tautomers") may occur. This can take the form of a proton tautomer in any one of the compounds containing an imino, keto, or oxime group, or a so-called valence tautomer in a compound containing an aromatic moiety. This means that a single compound can exhibit more than one isomer.

[0106] When geometric isomers are described by name or structure, it is understood that the named or described isomer exists to a greater extent than the other isomers, i.e., the geometric isomeric purity of the named or described geometric isomer is greater than 50 wt%, for example, at least 60 wt%, 70 wt%, 80 wt%, 90 wt%, 99 wt%, or 99.9 wt% pure. Geometric isomeric purity is determined by dividing the weight of the named or described geometric isomer in the mixture by the total weight of all geometric isomers in the mixture.

[0107] The cis / trans isomers can be separated by conventional techniques well known to those skilled in the art, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers / diastereomers include chiral synthesis from a suitable optically pure precursor, or the separation of racemates (or racemates of salts or derivatives) using, for example, chiral high-pressure liquid chromatography (HPLC). Alternatively, a racemate (or racemic precursor) can be reacted with a suitable optically active compound, such as an alcohol, or, if any one of the compounds in the above formulas contains an acidic or basic moiety, with a base or acid, such as 1-phenylethylamine or tartaric acid. The resulting diastereomer mixture can be separated by chromatography and / or fractional crystallization, and one or both of the diastereoisomers can be converted to the corresponding pure enantiomer by means well known to those skilled in the art. Any one of the chiral compounds of the above formulas (and their chiral precursors) can be obtained in enantiomer-rich form by chromatography, typically HPLC, on an asymmetric resin using a mobile phase consisting of a hydrocarbon, typically 0-50%, usually 2-20% by volume, isopropanol, and an alkylamine, typically 0.1% by volume, heptane or hexane containing 0-5% by volume, typically 0.1% diethylamine. The enriched mixture can be obtained by concentrating the eluate. Chiral chromatography using subcritical and supercritical fluids can be employed. Methods for chiral chromatography useful in some embodiments of this disclosure are known in the art (see, for example, Smith, Roger M., Loughborough University, Loughborough, UK; Chromatographic Science Series (1998), Vol. 75 (Supercritical Fluid Chromatography with Packed Columns), pp. 223-249, and the references cited therein). Columns can be obtained from Chiral Technologies, Inc., West Chester, Pa., USA, a subsidiary of Daicel® Chemical Industries, Ltd., Tokyo, Japan.

[0108] Any one of the compounds in the above formulas is illustrated herein in a single tautomer form, and it should be emphasized that all possible tautomer forms are included within the scope of this disclosure. 3. Administration and Medication Typically, the compounds of this disclosure are administered in amounts effective to treat conditions such as those described herein. The compounds of this disclosure may be administered as the compounds themselves or, instead, as pharmaceutically acceptable salts. For the purposes of administration and drug delivery, the compounds themselves or any pharmaceutically acceptable salts thereof will be simply referred to as the compounds of this disclosure.

[0109] The compounds of this disclosure are administered by any suitable route, in the form of a pharmaceutical composition adapted to such route, and in a dose effective for the intended treatment. The compounds of this disclosure may be administered orally, rectally, vaginally, parenterally, or topically.

[0110] The compounds of this disclosure can be administered orally. Oral administration may involve swallowing to allow the compounds to enter the gastrointestinal tract, or it may involve oral or sublingual administration to allow the compounds to enter the bloodstream directly from the mouth.

[0111] In another embodiment, the compounds of this disclosure may also be administered directly into the bloodstream, intramuscularly, or viscerally. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, and subcutaneous administration. Suitable devices for parenteral administration include needle (including microneedle) syringes, needle-free injectors, and infusion techniques.

[0112] In another embodiment, the compounds of the Disclosure may be administered topically to the skin or mucous membrane, i.e., transdermally. In another embodiment, the compounds of the Disclosure may be administered intranasally or by inhalation. In another embodiment, the compounds of the Disclosure may be administered rectally or vaginally. In another embodiment, the compounds of the Disclosure may be administered directly to the eyes or ears.

[0113] The dosage regimen for the compounds and / or compositions containing the compounds herein is based on many factors, including the patient's type, age, weight, sex, and medical condition; the severity of the condition; the route of administration; and the activity of the specific compound used. Therefore, the dosage regimen can vary widely. In one embodiment, for the treatment of the indicated conditions discussed herein, the total daily dose of the compounds herein is typically about 0.001 to about 100 mg / kg (i.e., mg of the compounds herein per kg of body weight).

[0114] For oral administration, the composition may be provided in the form of tablets containing 0.1 to 500 milligrams of the active ingredient for symptomatic adjustment of the dosage to the patient. The pharmaceutical product typically contains about 0.01 mg to about 500 mg of the active ingredient. Intravenously, the dose may range from about 0.01 to 10 mg / kg / min during a constant rate of infusion.

[0115] Appropriate subjects under this disclosure include mammalian subjects, such as non-human mammals, primates, and rodents (mice, rats, hamsters, rabbits, etc.). In one embodiment, humans are appropriate subjects. Human subjects may be of any sex and at any stage of development. 4. Pharmaceutical compositions In another embodiment, the Disclosure includes pharmaceutical compositions. Such pharmaceutical compositions include compounds of the Disclosure present together with pharmaceutically acceptable carriers or excipients. Other pharmacologically active substances may also be present.

[0116] As used herein, “pharmaceutically acceptable carrier or excipient” includes any physiologically compatible solvent, dispersion medium, coating, antimicrobial and antifungal agent, isotonic agent and absorption retarder, etc. Examples of pharmaceutically acceptable carriers include one or more of water, physiological saline, phosphate-buffered saline, dextrose, glycerol, ethanol, etc., and combinations thereof, and the composition may include isotonic agents, such as sugars, sodium chloride, or polyhydric alcohols, such as mannitol or sorbitol. Pharmacoagulated substances, such as humectants or small amounts of auxiliary substances that enhance the shelf life or efficacy of antibodies or antibody portions, such as humectants or emulsifiers, preservatives or buffers.

[0117] The compositions of this disclosure may be in many forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable and drip-able solutions), dispersions or suspensions, tablets, pills, powders, liposomes, and suppositories. The form depends on the intended mode of administration and therapeutic use.

[0118] Typical compositions are in the form of injectable or drip-prescription solutions, similar to those commonly used for passive immunization of humans using antibodies. One mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In another embodiment, the antibody is administered by intravenous drip or injection. In yet another embodiment, the antibody is administered by intramuscular or subcutaneous injection.

[0119] The oral administration in solid dosage form may be present, for example, in separate units, each containing a predetermined amount of at least one compound of the present disclosure, such as hard capsules or soft capsules, pills, cachets, lozenges, or tablets. In another embodiment, the oral administration may be in powder or granular form. In another embodiment, the oral administration form is sublingual, such as lozenges. In such solid dosage forms, any one of the compounds of the above formulas is originally combined with one or more adjuvants. Such capsules or tablets may contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage form may also contain a buffer or may be prepared using an enteric coating.

[0120] In another embodiment, oral administration may be in liquid form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing an inert diluent commonly used in the art (e.g., water). Such compositions may also include adjuvants, such as wetting agents, emulsifiers, suspending agents, flavorings (e.g., sweeteners), and / or fragrances.

[0121] In another embodiment, the disclosure includes parenteral administration forms. Parenteral administration includes, for example, subcutaneous injection, intravenous injection, intraperitoneal injection, intramuscular injection, intrasternal injection, and intravenous infusion. Injectable preparations (i.e., sterile, injectable aqueous or oily suspensions) can be formulated using appropriate dispersants, wetting agents, and / or suspending agents according to the known art.

[0122] In another embodiment, the disclosure includes a topical administration form. "Topical administration" includes, for example, transdermal administration via a transdermal patch or iontophoresis device, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. Topical formulations may include compounds that enhance the absorption or penetration of the active ingredient through the skin or other affected area. When the compounds of this disclosure are administered by a transdermal device, administration is achieved using a patch of either a reservoir and porous membrane type or a solid matrix type. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, sprays, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages, and microemulsions. Liposomes can also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol, and propylene glycol. Penetration enhancers can be incorporated; see, for example, Finnin and Morgan, J. Pharm. Sci., Vol. 88: pp. 955-958, 1999.

[0123] Formulations suitable for topical administration to the eye include, for example, eye drops, in which the compounds of this disclosure are dissolved or suspended in a suitable carrier. Typical formulations suitable for intraocular or intraocular administration may be in the form of an intravenous infusion of a micronized suspension or solution in isotonic, pH-adjusted sterile saline. Other formulations suitable for intraocular or intraocular administration include ointments, biodegradable (i.e., absorbable gel sponge, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses, and particle or vesicle systems, such as niosomes or liposomes. Polymers, such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, cellulosic polymers, such as hydroxypropyl methylcellulose, hydroxyethylcellulose, or methylcellulose, or heteropolysaccharide polymers, such as gellan gum, can be incorporated together with preservatives, such as benzalkonium chloride. Such formulations can also be delivered by iontophoresis.

[0124] For intranasal or inhalation administration, the compounds of this disclosure are conveniently delivered in the form of a solution or suspension from a pump spray container squeezed or pump-injected by the patient, or in the form of an aerosol spray from a pressure vessel or nebulizer with the use of an appropriate propellant. Formulations suitable for intranasal administration are typically delivered in the form of a dry powder from a dry powder inhaler (either alone, as a mixture in a dry blend containing, for example, lactose, or as mixed component particles mixed with, for example, phospholipids, such as phosphatidylcholine), or as an aerosol spray from a pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of an appropriate propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may contain a bioadhesive, such as chitosan or cyclodextrin.

[0125] In another embodiment, the disclosure includes a rectal administration form. Such an administration form may be, for example, a suppository. Cocoa butter is a conventional suppository base, but various substitutes can be used as appropriate.

[0126] Other carrier materials and administration methods known in the pharmaceutical field may also be used. The pharmaceutical compositions of this disclosure can be prepared by any of the well-known pharmaceutical techniques, such as effective formulation and administration procedures.

[0127] The above considerations regarding effective formulation and administration procedures are well known in the art and are described in standard textbooks. Drug formulation is discussed, for example, in Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1975; Liberman et al., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Kibbe et al., Handbook of Pharmaceutical Excipients (3rd edition), American Pharmaceutical Association, Washington, 1999. 5. Treatment Method This disclosure relates to SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A), or (III-B) (including all embodiments thereof), in which inhibition of the interaction between SOS1 and RAS family proteins and / or RAC1 is therapeutically beneficial and useful for treating and / or preventing diseases and / or conditions, including but not limited to the treatment and / or prevention of cancer.

[0128] In one embodiment, the present disclosure relates to compounds of formula (I), (II), (III-A), or (III-B), pharmaceutically acceptable salts thereof, or stereoisomers for use as pharmaceuticals.

[0129] In one embodiment, the present disclosure relates to compounds (I), (II), (III-A), or (III-B), pharmaceutically acceptable salts thereof, or stereoisomers for use in methods of treating the body of a human or animal.

[0130] In one embodiment, the present disclosure relates to SOS1 inhibitor compounds for use in the treatment and / or prevention of diseases and / or conditions, including, but not limited to, the treatment and / or prevention of cancer, where inhibition of the interaction between SOS1 and RAS family proteins and / or RAC1 is therapeutically beneficial, particularly compounds (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts, or stereoisomers.

[0131] In one embodiment, the present disclosure relates to SOS1 inhibitor compounds, particularly compounds (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts, or stereoisomers, for use in the treatment and / or prevention of cancer.

[0132] In one embodiment, the present disclosure relates to SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts, or stereoisomers, for use in methods of treating and / or preventing cancer in the body of humans or animals.

[0133] In one embodiment, the disclosure relates to SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A) or (III-B), pharmaceutically acceptable salts or stereoisomers thereof, for use as defined above, administered before, after, or together with at least one other pharmacologically active substance.

[0134] In one embodiment, the disclosure relates to an SOS1 inhibitor compound, or a pharmaceutically acceptable salt thereof, for use as defined above, which is administered in combination with at least one other pharmacologically active substance.

[0135] In one embodiment, the disclosure relates to a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof, for use as defined above, to be administered in combination with at least one other pharmacologically active substance.

[0136] In one embodiment, the present disclosure relates to a pharmacologically active substance prepared to be administered before, after, or together with a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt thereof, or a stereoisomer, for use as previously defined.

[0137] In one embodiment, the present disclosure relates to pharmacologically active substances prepared to be administered before, after, or together with a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt, or a stereoisomer thereof, for use as previously defined for the use of a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt, or a stereoisomer thereof.

[0138] In one embodiment, the present disclosure relates to SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts, or stereoisomers, for use in treatments or methods of treatment as defined above.

[0139] In one embodiment, the present disclosure relates to the use of SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts, or stereoisomers, for preparing pharmaceutical compositions for the treatment and / or prevention of cancer.

[0140] In one embodiment, the disclosure relates to the use of an SOS1 inhibitor compound, as previously defined, or a pharmaceutically acceptable salt thereof, wherein the SOS1 inhibitor compound is administered before, after, or together with at least one other pharmacologically active substance.

[0141] In one embodiment, the disclosure relates to the use of a compound of formula (I), (II), (III-A), or (III-B) as previously defined, a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is administered before, after, or together with at least one other pharmacologically active substance.

[0142] In one embodiment, the present disclosure relates to the use of, for treatment, a previously defined SOS1 inhibitor compound, in particular, a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof.

[0143] In one embodiment, the present disclosure relates to a method for treating and / or preventing a disease and / or condition, wherein inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial, and the method comprises the step of administering a therapeutically effective amount of an SOS1 inhibitor compound, in particular a compound of formula (I), (II), (III-A) or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof, to a human.

[0144] In one embodiment, the present disclosure relates to a method for the treatment and / or prevention of cancer, comprising the step of administering to a human being a therapeutically effective amount of an SOS1 inhibitor compound, in particular a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof.

[0145] In one embodiment, the present disclosure relates to a method, as previously defined, in which an SOS1 inhibitor compound, or a pharmaceutically acceptable salt thereof, is administered before, after, or together with at least one other pharmacologically active substance.

[0146] In one embodiment, the present disclosure relates to a method, as previously defined, in which a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof, is administered before, after, or together with at least one other pharmacologically active substance.

[0147] In one embodiment, the present disclosure relates to a method, as previously defined, in which an SOS1 inhibitor compound, or a pharmaceutically acceptable salt thereof, is administered in combination with at least one other pharmacologically active substance in a therapeutically effective amount.

[0148] In one embodiment, the present disclosure relates to a method, as previously defined, in which a compound of formula (I), (II), (III-A), or (III-B), a pharmaceutically acceptable salt or stereoisomer thereof, is administered in combination with at least one other pharmacologically active substance in a therapeutically effective amount.

[0149] In one embodiment, the present disclosure relates to a method for a procedure as defined above. In one embodiment, the diseases / conditions / cancers treated / prevented by SOS1 inhibitor compounds as defined herein (above or below), SOS1 inhibitor compounds for use, compounds of formula (I), compounds of formula (I) for use, uses for preparation, and methods for treatment and / or prevention are selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, and sarcoma.

[0150] In one embodiment, the disease / condition / cancer treated / prevented by using an SOS1 inhibitor compound as defined herein (above or below), an SOS1 inhibitor compound for use, a compound of formula (I), a compound of formula (I) for use, a use for preparation, and a method for treatment and / or prevention is selected from the group consisting of pancreatic cancer, lung cancer (preferably non-small cell lung cancer (NSCLC)), cholangiocarcinoma, and colorectal cancer.

[0151] In one embodiment, the disease / condition treated / prevented using SOS1 inhibitor compounds as defined herein (above or below), SOS1 inhibitor compounds for use, compounds of formula (I), compounds of formula (I) for use, uses for preparation, and methods for treatment and / or prevention is rhasopathy. In one embodiment, this is selected from the group consisting of neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Noonan syndrome with lentigo multifocals (NSML) (also known as LEOPARD syndrome), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facio-cutaneous syndrome (CFC), Regius syndrome (also known as NF1-like syndrome), and hereditary gingival fibromatosis.

[0152] In one embodiment, the SOS1 inhibitor compounds as defined herein (above or below), particularly compounds of formula (I), (II), (III-A), or (III-B), together with / in combination with their pharmaceutically acceptable salts or stereoisomers, or pharmacologically active substances used in methods of medical use, use, treatment, and / or prevention, may be selected from one or more of the following:

[0153] 1. Inhibitors of EGFR and / or its mutants a. For example, afatinib, erlotinib, gefitinib, lapatinib, cetuximab, panitumumab, osimertinib, olmutinib, EGF-816; b. Afatinib, osimertinib, and cetuximab; or c. Afatinib; 2. Inhibitors of ErbB2 (Her2) and / or its mutants a. For example, afatinib, lapatinib, trastuzumab, pertuzumab; b. Afatinib and trastuzumab; c. Trastuzumab; 3. Inhibitors of ALK and / or its mutants a. For example, crizotinib, alectinib, entrectinib, brigatinib; b. Crizotinib and alectinib; c. Crizotinib; 4. Inhibitors of MEK and / or its mutants a. For example, trametinib, cobimetinib, binimetinib, selumetinib, refametinib; b. Trametinib and cobimetinib; c. Trametinib; 5. Inhibitors of GDP-conjugated KRAS and / or its mutants a. Irreversible inhibitors of KRAS G12C i. For example, ARS-853 (compound V-64 in WO2014 / 152588), Example I-272 in WO2016 / 044772; b. Reversible inhibitors of GDP-bound KRAS and / or its mutants 6. Inhibitors of BCR-ABL and / or its mutants a. For example, imatinib, dasatinib, nilotinib; b. Imatinib and nilotinib; c. Imatinib; 7. Inhibitors of FGFR1 and / or FGFR2 and / or FGFR3 and / or their mutants a. For example, nintedanib; 8. Inhibitors of ROS1 and / or its mutants a. For example, crizotinib, entrectinib, lorlatinib, ceritinib, merestinib; b. Crizotinib and entrectinib; c. Crizotinib; 9. Inhibitors of c-MET and / or its mutants 10. Inhibitors of AXL and / or its mutants 11. Inhibitors of NTRK1 and / or its mutants 12. Inhibitors of RET and / or its mutants 13. Taxane a. For example, paclitaxel, nab-paclitaxel, docetaxel; b. Paclitaxel; 14.Platinum-containing compounds a. For example, cisplatin, carboplatin, oxaliplatin; 15. Antimetabolites a. For example, a combination of 5-fluorouracil, capecitabine, phloxuridine, cytarabine, gemcitabine, trifluridine, and tipiracil (=TAS102); b. Gemcitabine; 16. Mitotic kinase inhibitors a. For example, CDK4 / 6 inhibitors i. For example, palbociclib, ribociclib, abemaciclib; ii. Palbociclib and abemaciclib; iii. Abemaciclib; 17. Immunotherapy agents a. For example, immune checkpoint inhibitors i. For example, anti-CTLA4 mAb, anti-PD1 mAb, anti-PD-L1 mAb, anti-PD-L2 mAb, anti-LAG3 mAb, anti-TIM3 mAb; ii. Anti-PD1 mAb; iii. For example, ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, pizilizumab, PDR-001 (=spartalizumab); iv. Nivolumab, pembrolizumab, and PDR-001 (=spartalizumab); v. Pembrolizumab; 18. Anti-angiogenic drugs a. For example, bevacizumab, nintedanib; b. Bevacizumab; 19. Topoisomerase inhibitors a. For example, irinotecan, irinotecan liposome, topotecan; b. Irinotecan; 20. Inhibitors of A-Raf and / or B-Raf and / or C-Raf and / or their mutants a. For example, RAF-709 (=Example 131 in WO2014 / 151616), LY-3009120 (=Example 1 in WO2013 / 134243); 21. Inhibitors of ERK and / or its mutants a. For example, urixertinib; 22. Apoptosis regulators a. For example, inhibitors of the interaction between p53 (functional p53, wtp53) and MDM2 ("MDM2 inhibitors"); i. For example, HDM-201, NVP-CGM097, RG-7112, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-1 15; ii. HDM-201, RG-7388 and AMG-232 b. For example, PARP inhibitors; c. For example, MCL-1 inhibitors; 23. mTOR inhibitors a. For example, rapamycin, temsirolimus, everolimus, ridaflorimus; 24. Epigenetic modifiers a. For example, BET inhibitors i. For example, JQ-1, GSK525762, OTX015 (=MK8628), CPI0610, TEN-010 (=R06870810); b. For example, CDK9 inhibitors; 25. Inhibitors of IGF1 / 2 and / or IGF1-R a. For example, zentuzumab (antibody 60833 in WO2010 / 066868), MEDI-573 (= dusigituzumab); 26. Inhibitors of RAS GEF and / or its mutants a. For example, inhibitors of SOS2 and / or its mutants. 27. Inhibitors of PI3K and / or its mutants 28. Inhibitors of SHP2 and / or its mutants In one embodiment, non-pharmacological therapies can be used, as specified herein (above or below), with / in combination with SOS1 inhibitor compounds, particularly compounds of formula (I), (II), (III-A), or (III-B), their pharmaceutically acceptable salts or stereoisomers, or in methods of medical use, treatment, and / or prevention. Examples of non-pharmacological treatments include, but are not limited to, radiotherapy, cryotherapy, hyperthermia, surgery (e.g., surgical excision of tumor tissue), and T-cell adoptive transplantation (ACT) therapy.

[0154] In one embodiment, the compounds of the Disclosure may be used as adjuvant therapy after surgery. In some embodiments, the compounds of the Disclosure may be used as neoadjuvant therapy after surgery.

[0155] Radiotherapy can be used to inhibit abnormal cell growth in a subject (e.g., a mammal (e.g., a human)) or to treat hyperproliferative disorders, such as cancer. Techniques for administering radiotherapy are publicly known in the art. Radiotherapy can be administered through one or a combination of several methods, including, but not limited to, external beam radiation therapy, internal radiation therapy, brachytherapy, stereotactic radiation therapy, total body radiation therapy, radiotherapy, and permanent or temporary interstitial brachytherapy. The term “brachytherapy,” as used herein, refers to radiotherapy in which spatially localized radioactive material is delivered by insertion of a tumor or other proliferative tissue disease site in the body or near it. The term is intended to include, without limitation, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and radioisotopes of Lu). Suitable radiation sources for use as cell conditioners in this disclosure include both solid and liquid. In non-limiting examples, a radiation source may be a radionuclide, e.g., I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The radioactive material may be a fluid prepared from a solution of any radionuclide, for example, a solution of I-125 or I-131, or the radioactive fluid may be prepared using a suitable fluid slurry containing fine particles of a solid radionuclide, for example, Au-198 or Y-90. Furthermore, the radionuclide can be incorporated into a gel or radioactive microsphere.

[0156] In one embodiment, the compounds of the Disclosure can make abnormal cells more sensitive to radiation therapy for the purpose of killing or inhibiting the growth of such cells. Accordingly, the Disclosure relates to a method for conferring sensitivity of abnormal cells in a mammal to radiation therapy, comprising the step of administering to a mammal an amount of the compound of the Disclosure effective in conferring sensitivity of abnormal cells to radiation therapy. The amount of compound in this method can be determined by means for determining an effective amount of the compound described herein. In some embodiments, the compounds of the Disclosure may be used as adjuvant therapy after radiotherapy or as neoadjuvant therapy before radiotherapy.

[0157] In one embodiment, the non-pharmacological treatment is T cell adoptive transplantation (ACT) therapy. In some embodiments, the T cells are activated T cells. The T cells may be modified to express a chimeric antigen receptor (CAR). CAR-modified T (CAR-T) cells can be generated by any method known in the art. For example, CAR-T cells can be generated by introducing a suitable expression vector encoding a CAR into T cells. Before increasing and genetically modifying the T cells, a source of T cells is obtained from the subject. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymic tissue, tissue from infection sites, ascites, pleural fluid, spleen tissue, and tumors. In certain embodiments of this disclosure, any number of T cell lines available in the art may be used. In some embodiments, the T cells are autologous T cells. Either before or after genetic modification of T cells to express a desired protein (e.g., CAR), T cells can generally be activated and increased using methods such as those described in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 7,572,631; 5,883,223; 6,905,874; 6,797,514; and 6,867,041.

[0158] In one embodiment, an additional therapeutic agent may be used in combination with / in combination with an SOS1 inhibitor compound, particularly a compound of formula (I), (II), (III-A), or (III-B), such as those specified herein (above or below), or with a pharmaceutically acceptable salt or stereoisomer thereof, or in a method of medical use, application, treatment, and / or prevention.

[0159] In one embodiment, the additional therapeutic agent may be a steroid. Therefore, in some embodiments, one or more additional therapeutic agents may be steroids. Suitable steroids include, but are not limited to, 21-acetoxypregnenolone, alclomethasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, crocortol, cloprednol, corticosterone, cortisone, cortibazole, deflazacort, desonide, desoxymethasone, dexamethasone, diflorasone, diflucortol, difprednate, enoxolone, fluazacort, fluchloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, flupredniden acetate, Examples include fluprednisolone, flulandrenolide, fluticasone propionate, formocortal, halcinonide, halobetazole propionate, halomethasone, hydrocortisone, loteprednol etabonate, mazipredone, medrisone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, thixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexaacetonide, and their salts or derivatives.

[0160] Further examples of therapeutic agents that can be used in combination therapy with the compounds of this disclosure include the following patents: U.S. Patents Nos. 6,258,812, 6,630,500, 6,515,004, 6,713,485, 5,521,184, 5,770,599, 5,747,498, 5,990,141, 6,235,764, and 8,623,885, as well as international patent application W Examples of compounds include those described in O01 / 37820, WO01 / 32651, WO02 / 68406, WO02 / 66470, WO02 / 55501, WO04 / 05279, WO04 / 07481, WO04 / 07458, WO04 / 09784, WO02 / 59110, WO99 / 45009, WO00 / 59509, WO99 / 61422, WO00 / 12089, and WO00 / 02871.

[0161] The therapeutic agent may be a biologic (e.g., cytokines (e.g., interferons or interleukins, e.g., IL-2)) used in the treatment of cancer or related conditions. In some embodiments, the biologic is an immunoglobulin-based biologic, such as a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof), that activates a target to stimulate an anti-cancer response or antagonizes an antigen important to cancer. Antibody-drug conjugates are also an example.

[0162] The therapeutic agent may be a checkpoint inhibitor. In one embodiment, the checkpoint inhibitor is an inhibitory antibody (e.g., a monospecific antibody, e.g., a monoclonal antibody). The antibody may be, for example, humanized or fully human. In some embodiments, the checkpoint inhibitor is a fusion protein, e.g., an Fc receptor fusion protein. In some embodiments, the checkpoint inhibitor is a drug that interacts with a checkpoint protein, e.g., an antibody. In some embodiments, the checkpoint inhibitor is a drug that interacts with a ligand of a checkpoint protein, e.g., an antibody. In some embodiments, the checkpoint inhibitor is a CTLA-4 inhibitor (e.g., an inhibitor antibody or small molecule inhibitor) (e.g., an anti-CTLA-4 antibody or fusion protein). In some embodiments, the checkpoint inhibitor is a PD-1 inhibitor or antagonist (e.g., an inhibitor antibody or small molecule inhibitor). In some embodiments, the checkpoint inhibitor is a PD-1 inhibitor or antagonist (e.g., an inhibitor antibody or small molecule inhibitor). In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist of PDL-2 (e.g., an inhibitor antibody or an Fc fusion or small molecule inhibitor) (e.g., a PDL-2 / Ig fusion protein). In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist of B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, B-7 family ligands, or combinations thereof (e.g., an inhibitor antibody or a small molecule inhibitor).In some embodiments, the checkpoint inhibitor is pembrolizumab, nivolumab, PDR001 (NVS), REGN2810 (Sanofi / Regeneron), PD-L1 antibody, e.g., avelumab, durvalumab, atezolizumab, pizilizumab, JNJ-63723283 (JNJ), BGB-A317 (BeiGene & Celgene), or, to some extent, These include ipilimumab, tremelimumab, nivolumab, pembrolizumab, AMP224, AMP514 / MEDI0680, BMS936559, MEDl4736, MPDL3280A, MSB0010718C, BMS986016, IMP321, lirirumab, IPH2101, 1-7F9, and KW-6002, which are checkpoint inhibitors disclosed in Preusser, M. et al. (2015) Nat. Rev. Neurol.

[0163] The therapeutic agent may be a drug that treats cancer or related conditions (e.g., cytotoxic agents, non-peptide small molecules or other compounds useful in treating cancer or related conditions, collectively referred to as "anticancer agents"). Anticancer agents may be, for example, chemotherapeutic agents or targeted therapy agents.

[0164] Anticancer agents include mitotic inhibitors, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, alkylating agents, antimetabolites, folate analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-asparaginase, topoisomerase inhibitors, interferons, platinum-coordinated complexes, anthracendione-substituted ureas, methylhydrazine derivatives, corticosteroids, progestins, estrogens, antiestrogens, androgens, and gonadotropin-releasing hormone analogs. Further anticancer agents include leucovorin (LV), irinotecan, oxaliplatin, capecitabine, paclitaxel, and docetaxel. In some embodiments, one or more additional treatments comprise two or more anticancer agents. Two or more anticancer drugs can be used in a cocktail, either administered in combination or separately. Appropriate drug regimens for combination anticancer drugs are publicly known in the art and are described, for example, in Saltz et al., Proc. Am. Soc. Clin. Oncol. Vol. 18:p. 233a (1999), and Douillard et al., Lancet Vol. 355 (No. 9209):p. 1041-1047 (2000).

[0165] Other non-exclusive examples of anticancer drugs include Gleevec® (imatinib mesylate); Kyprolis® (carfilzomib); Velcade® (bortezomib); Casodex (bicalutamide); Iressa® (gefitinib); alkylating agents, e.g., thiotepa, cyclophosphamide; alkyl sulfonates, e.g., busulfan, improsulfan, piposulfan; aziridines, e.g., benzodopa, carbocon, metredopa, uredopa; altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine (trimethylolomelamine), ethyleneimines and methylamines; acetogenins (especially bratacin and bratacinone); camptothecin (including its synthetic analog topotecan); briostatin; calistatin; CC-1065 (its adzeresin, carzeresin, and (Including bizeresin synthetic analogs); cryptophycin (especially cryptophycin 1 and cryptophycin 8); dorastatin; duocalmycin (including synthetic analogs, KW-2189 and CB1-TM1); erterobin; pancratistatin; sarcodicin A; spongstatin; nitrogen mustard, e.g., chlorambucil, chlornafadin, colophosphamide, estramustine, ifosfamide Mechloretamine, mechloretamine oxide hydrochloride, melphalan, nobembitine, fenestrine, prednimustine, trophosphamide, uracil mustard; nitrosourea, e.g., carmustine, chlorozotocin, photemustine, lomustine, nimustine, ranimustine; antibiotics, e.g., engine antibiotics (e.g., calicheamicin, e.g., calicheamicin gamma 1I and calicheamicin omega I1, etc. (see, e.g., Agnew, Chem. Intl., Engl. Vol. 33: pp. 183-186 (1994)); dynemycin, e.g., dynemycin A; bisphosphonates, e.g., clodronate; esperamycin;Neocardinostatin chromophore and related pigment protein enediin antibiotics: chromophore, acrasinomycin, actinomycin, autoramycin, azaserin, bleomycin, kactinomycin, calicheamicin, carabicin, caminomycin, carminomycin, cardinophilin, chromomycin, dactinomycin, daunorubicin, detrubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (adriamycin), morpholino-doxorubicin, shea Nomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin, e.g., mitomycin C, mycophenolic acid, nogaramycin, olibomycin, peplomycin, potophyllomycin, puromycin, keramycin, rhodorubicin, streptonigrin, streptozocin, tubercidine, ubenimex, dinostatin, zolubicin; antimetabolites, e.g., methotrexate, 5-fluorouracil (5-FU); folic acid analogs, e.g., deno Pterin, pteropterin, trimethrexate; purine analogs, e.g., fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs, e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, e.g., carsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; anti-adrenal agents, e.g., aminoglutethimide, mitotane, trilostane; folic acid supplements, e.g., floric acid Aceglutone; Aldophosphamide glycoside; Aminolevulinic acid; Enyluracil; Amsacrine; Bestrabusil; Bisanthren; Edatraxate; Dehofamine; Demecolsin; Diadicone; Elformitin; Erliptinium acetate; Epotilone, e.g., Epotilone B; Etoglucid; Gallium nitrate; Hydroxyurea; Lentinan; Ronidamine; Maytansinoids, e.g., Maytansine and Ansamitosine; Mitoguazone; Mitoxanthrone; Mopidamole; Nitracrine; Pentostatin; Fenamet; Pirarubicin; Rosoxanthrone;Podophyllic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; lyzoxin; schizophyllan; spirogermanium; tenuazonic acid; triadicone; 2,2',2''-trichlorotriethylamine; trichothecenes, e.g., T-2 toxin, beracrine A, loridine A and anguidin; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitractol; pipobromane; gasitosine; arabinoside ("Ara-C"); cyclophosphatidyl Mido; thiotepa; taxoids, e.g., Taxol® (paclitaxel), Abraxane® (cremohol-free, nanoparticle formulation with modified albumin of paclitaxel), Taxotere® (docetaxel); chlorambucil; tamoxifen (Nolvadex®); raloxifene; aromatase inhibitor 4(5)-imidazole; 4-hydroxytamoxifen; trioxyfen; keoxyfen; LY 117018; Onapristone; Toremifene (Fareston®); Flutamide, Niltamide, Bicalutamide, Leuprolide, Goserelin; Chlorambucil; Gemzar® Gemcitabine; 6-Thiogunine; Mercaptopurine; Platinum-coordinated complexes, e.g., cisplatin, oxaliplatin, and carboplatin; Vinblastine; Platinum; Etoposide (VP-16); Ifosfamide; Mitoxantrone; Vincristine; Navelbine® (Vinorelbine); Novantrone; Teniposide; Edatrexate; Daunomycin; Aminopterin; Ibandronate; Irinotecan (e.g., CPT-11); Topoisomerase inhibitors RFS Examples include difluoromethylornithine (DMFO); retinoids, e.g., retinoic acid; esperamycin; capecitabine (e.g., Xeloda®); and any pharmaceutically acceptable salts of the above.

[0166] Further non-exclusive examples of anticancer drugs include trastuzumab (Herceptin®), bevacizumab (Avastin®), cetuximab (Erbitux®), rituximab (Rituxan®), Taxol®, Arimidex®, ABVD, Avisin, avagovomab, acridine carboxamide, adecatumumab, and 17-N-allylamino-17 - Demethoxygeldanamycin, alfarazine, arbocidib, 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone, amonafide, anthracendione, anti-CD22 immunotoxin, anti-cancer agents (e.g., cell cycle nonspecific anti-cancer agents, and other anti-cancer agents described herein), antitumor-forming herbs, apadicon, atiprimod, azathioprine, berotecan, bendamustine, BIBW 2992, Bilicodal, Brostarisin, Briostatin, Butionine sulfoximine, CBV (chemotherapy), Kalikrin, Dichloroacetate, Discodermorid, Elsamitrusine, Enocitabine, Eribulin, Exatecan, Exislind, Ferginol, Forodesine, Phosfestrol, ICE chemotherapy regimen, IT-101, Imexone, Imiquimod, Indocarbazole, Ilofluben, Lanicidal, Lalotaxel, Lenalidomide, Lucanton, Lulutotecan, Maphosfamide, Mitozolomide, Examples include naphoxidine, nedaplatin, olaparib, ortataxel, PAC-1, pawpaw, pixantrone, proteasome inhibitors, rebeccamycin, regiquimod, rubitecan, SN-38, salinosporamide A, sapacitabine, stanford V, swinesonin, talaporfin, talikidal, tegafur-uracil, temodal, tesetaxel, triplatin tetranitrate, tris(2-chloroethyl)amine, troxacin, uramustine, bajimezan, vinflunin, ZD6126, and zoskidal.

[0167] Further non-limiting examples of anticancer agents include natural products, e.g., vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), epidipodophyllotoxins (e.g., etoposide and teniposide), antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin, and idarubicin), anthracyclines, mitoxantrone, bleomycin, plicamycin (mitramycin), mitomycin, enzymes (e.g., L-asparaginase, which systemically metabolizes L-asparagine and deprives cells that lack the ability to synthesize asparagine on their own), antiplatelet agents, antiproliferative / antimitotic alkylating agents, e.g., nitrogen mustards (e.g., mechloretamine, cyclophosphamide and its analogs, melphalan, and chlorambucil), ethyleneimines and methylmelamines (e.g., hexamethylmelamine and thiotepa), and CDK inhibitors (CDK 4 / 6 inhibitors (e.g., ribociclib, abemaciclib, or palbociclib), sericlib, UCN-01, P1446A-05, PD-0332991, dinacyclib, P27-00, AT-7519, RGB286638, and SCH727965), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine (BCNU) and its analogs, as well as streptozocin), trazeneth-dacarbadinine (DTIC), antiproliferative / anti-proliferative antimetabolites (e.g., folate analogs, pyrimidine analogs (e.g., fluorouracil, floxul) Lysine and cytarabine), purine analogs and related inhibitors (e.g., mercaptopurine, thioguanine, pentostatin, and 2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole, exemestane, and letrozole), and platinum-coordinate complexes (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide, histone deacetylase (HDAC) inhibitors (e.g., trichostatin, sodium butyrate, apicidan, suberoyl anilide hydroamic acid)PI3K inhibitors (e.g., volinostat, LBH589, romidepsin, ACY-1215, and panobinostat), mTOR inhibitors (e.g., vistucertib, temsirolimus, everolimus, ridaflorimus, and sirolimus), KSP (Eg5) inhibitors (e.g., Array520), DNA binders (e.g., Zalypsis®), PI3K inhibitors, e.g., PI3K delta inhibitors (e.g., GS-1101 and TGR-1202), PI3 K delta and gamma inhibitors (e.g., CAL-130), copanlisib, alpelisib, and idelalisib; multikinase inhibitors (e.g., TG02 and sorafenib); hormones (e.g., estrogen) and hormone agonists, e.g., luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide, and triptorelin); BAFF neutralizing antibodies (e.g., LY2127399); IKK inhibitors; p38MAPK inhibitors Drugs, anti-IL-6 (e.g., CNT0328), telomerase inhibitors (e.g., GRN163L), aurora kinase inhibitors (e.g., MLN8237), cell surface monoclonal antibodies (e.g., anti-CD38 (HUMAX-CD38), anti-CSl (e.g., elotuzumab), HSP90 inhibitors (e.g., 17AAG and KOS953), P13K / Akt inhibitors (e.g., perifosine), Akt inhibitors (e.g., GSK-2141795), PKC inhibitors (e.g., elotuzumab) Examples include olaparib and veliparib (ABT-888), as well as BCL-2 antagonists.

[0168] In some embodiments, the anticancer agent is selected from mechloretamine, camptothecin, ifosfamide, tamoxifen, raloxifene, gemcitabine, Navelbine®, sorafenib, or any of the aforementioned analogues or derivative variants.

[0169] In some embodiments, the anticancer agent is an ALK inhibitor. Non-limiting examples of ALK inhibitors include ceritinib, TAE-684 (NVP-TAE694), PF02341066 (crizotinib or 1066), alectinib; brigatinib; entrectinib; ensartinib (X-396); lorlatinib; ASP3026; CEP-37440; 4SC-203; TL-398; PLB1003; TSR-011; CT-707; TPX-0005 and AP26113. Examples of additional ALK kinase inhibitors are described in Examples 3-39 of WO05016894.

[0170] In some embodiments, the anticancer agent is an inhibitor of a downstream member of a receptor tyrosine kinase (RTK) / growth factor receptor (e.g., SHP2 inhibitors (e.g., SHP099, TNO155, RMC-4550, RMC-4630, JAB-3068), another SOS1 inhibitor (e.g., BI-1701963), a Raf inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, or an mTOR inhibitor (e.g., an mTORC1 inhibitor or an mTORC2 inhibitor). In some embodiments, the anticancer agent is JAB-3312. In some embodiments, the anticancer agent is a Ras inhibitor (e.g., AMG510, MRTX1257, LY349946, MRTX849, ARS-3248 (JNJ-74699157), or ARS-1620) or a Ras vaccine, or another treatment designed to directly or indirectly reduce the oncogenic activity of Ras.

[0171] In some embodiments, the Ras protein is wild-type. In some embodiments, the cancer contains a Ras mutation. In some embodiments, the mutation is (a) The following K-Ras mutants: G12D, G12V, G12C, G13D, G12R, G12A, Q61H, G12S, A146T, G13C, Q61L, Q61R, K117N, A146V, G12f, Q61K, L19F, Q22K, V14I, A59T, A146P, G13R, G12L or G13V, and combinations thereof; (b) The following H-Ras mutants: Q61R, G13R, Q61K, G12S, Q61L, G12D, G13V, G13D, G12C, K117N, A59T, G12V, G13C, Q61H, G13S, A18V, D119N, G13N, A146T, A66T, G12A, A146V, G12N, or G12R and combinations thereof; and (c) The following N-Ras mutants: Q61R, Q61K, G12D, Q61L, Q61H, G13R, G13D, G12S, G12C, G12V, G12A, G13V, G12R, P185S, G13C, A146T, G60E, Q61P, A59D, E132K, E49K, T50I, A146V or A59T, and combinations thereof; Alternatively, one of the aforementioned combinations (e.g., both K-Ras G12C and K-Ras G13C) is selected. In some embodiments, the cancer includes a Ras mutation selected from the group consisting of G12C, G13C, G12A, G12D, G13D, G12S, G13S, G12V, and G13V.

[0172] In some embodiments, therapeutic agents that may be combined with the compounds of this disclosure are inhibitors of the MAP kinase (MAPK) pathway (or "MAPK inhibitors"). Examples of MAPK inhibitors include, but are not limited to, one or more MAPK inhibitors described in Cancers (Basel) September 2015; Vol. 7 (No. 3): pp. 1758-1784. For example, MAPK inhibitors include trametinib, binimetinib, selumetinib, cobimetinib, LErafAON (NeoPharm), ISIS5132; vemurafenib, pimacertib, TAK733, RO4987655 (CH4987655); CI-1040; PD-0325901; CH5126766; MAP855; AZD6244; refametinib (RDEA119 / BAY86-9766); GDC-0973 / XL581; AZD8330 (ARRY-424704 / ARRY-704); RO5126766 (Roche, PLoS One or more of the following can be selected: One. November 25, 2014; described in Vol. 9 (No. 11); and GSK1120212 (or JTP-74057, described in Clin Cancer Res. March 1, 2011; Vol. 17 (No. 5): pp. 989-1000).

[0173] In some embodiments, the anticancer agent is a disruptor or inhibitor of the RAS-RAF-ERK, PI3K-AKT-TOR, or PI3K-AKT signaling pathway. Examples of PI3K / AKT inhibitors include, but are not limited to, one or more PI3K / AKT inhibitors listed in Cancers (Basel) September 2015; Vol. 7 (No. 3): pp. 1758-1784. For example, the PI3K / AKT inhibitor may be selected from one or more of NVP-BEZ235; BGT226; XL765 / SAR245409; SF1126; GDC-0980; PI-103; PF-04691502; PKI-587; GSK2126458.

[0174] In some embodiments, the anticancer agent is a PD-1 or PD-L1 antagonist. In some embodiments, additional therapeutic agents include EGFR inhibitors, IGF-1R inhibitors, MEK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors, and immunotherapies.

[0175] IGF-1R inhibitors include lincitinib or its pharmaceutically acceptable salts. EGFR inhibitors include, but are not limited to, small molecule antagonists, antibody inhibitors, or specific antisense nucleotides or siRNAs. Useful antibody inhibitors of EGFR include cetuximab (Erbitux®), panitumumab (Vectibix®), zaltumumab, nimotuzumab, and matuzumab. Further antibody-based EGFR inhibitors include any anti-EGFR antibody or antibody fragment that can partially or completely block EGFR activation by its native ligand. Non-limiting examples of antibody-based EGFR inhibitors include those described in Modjtahedi et al., Br. J. Cancer 1993, Vol. 67: pp. 247-253; Teramoto et al., Cancer 1996, Vol. 77: pp. 639-645; Goldstein et al., Clin. Cancer Res. 1995, Vol. 1: pp. 1311-1318; Huang et al., Cancer Res. 15: Vol. 59 (No. 8): pp. 1935-40; and Yang et al., Cancer Res. 1999, Vol. 59: pp. 1236-1243. EGFR inhibitors may be monoclonal antibodies such as Mab E7.6.3 (Yang, 1999, above) or Mab C225 (ATCC accession number HB-8508), or antibodies or antibody fragments having binding specificity thereto.

[0176] Small molecule antagonists of EGFR include gefitinib (Iressa®), erlotinib (Tarceva®), and lapatinib (TykerB®). See, for example, Yan et al., Pharmacogenetics and Pharmacogenomics In Oncology Therapeutic Antibody Development, BioTechniques 2005, Vol. 39 (No. 4): pp. 565-568; and Paez et al., EGFR Mutations In Lung Cancer Correlation With Clinical Response To Gefitinib Therapy, Science 2004, Vol. 304 (No. 5676): pp. 1497-500. Further non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described in the following patent publications, and all pharmaceutically acceptable salts of such EGFR inhibitors: EP0520722; EP0566226; WO96 / 33980; U.S. Patent No. 5,747,498; WO96 / 30347; EP0787772; WO97 / 30034; WO97 / 30044; WO97 / 38994; WO97 / 49688; EP837063; WO98 / 02434; WO97 / 38983; WO95 / 19774; WO95 / 19970; WO97 / 13771; WO98 / 02437; WO98 / 024 38;WO97 / 32881;DE19629652;WO98 / 33798;WO97 / 32880;WO97 / 32880;EP682027;WO9 7 / 02266;WO97 / 27199;WO98 / 07726;WO97 / 34895;WO96 / 31510;WO98 / 14449;WO98 / 144 50; WO98 / 14451; WO95 / 09847; WO97 / 19065; WO98 / 17662; US Patent No. 5,789,427; US Patent No. 5,650,415; US Patent No. 5,656,643; WO99 / 35146; WO99 / 35132; WO99 / 07701; and WO92 / 20642.Additional non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described by Traxler et al., Exp. Opin. Ther. Patents 1998, Vol. 8 (No. 12): pp. 1599–1625. In some embodiments, the EGFR inhibitor is osimertinib.

[0177] MEK inhibitors include, but are not limited to, pimacertib, selumetinib, cobimetinib (Cotellic®), trametinib (Mekinist®), and binimetinib (Mektovi®). In some embodiments, the MEK inhibitor targets MEK mutations, namely class I MEK1 mutations selected from D67N;P124L;P124S; and L177V. In some embodiments, the MEK mutation is a class II MEK1 mutation selected from DE51-Q58;DF53-Q58;E203K;L177M;C121S;F53L;K57E;Q56P; and K57N.

[0178] PI3K inhibitors include, but are not limited to, woltmannin; 17-hydroxywoltmannin analog described in WO06 / 044453; 4-[2-(1H-indazole-4-yl)-6-[[4-(methylsulfonyl)piperazine-1-yl]methyl]thieno[3,2-d]pyrimidine-4-yl]morpholine (also known as pictilisib or GDC-0941, described in WO09 / 036082 and WO09 / 055730); 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinoline-3-yl)-2,3-dihydroimidazo[4,5-c]quinoline-1-yl]phenyl]propionitrile (BEZ 235 or NVP-BEZ Also known as 235, described in WO06 / 122806); (S)-l-(4-((2-(2-aminopyrimidine-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidine-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (described in WO08 / 070740); LY294002 (2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (available from Axon Medchem); PI 103 hydrochloride (3-[4-(4-morpholinylpyrido[3',2':4,5]fl[3,2-d]pyrimidine-2-yl]phenol hydrochloride (available from Axon Medchem); PIK 75(2-methyl-5-nitro-2-[(6-bromoimidazo[1,2-a]pyridine-3-yl)methylene]-1-methylhydrazide-benzenesulfonic acid, monohydrochloride) (available from Axon Medchem); PIK 90(N-(7,8-dimethoxy-2,3-dihydroimidazo[l,2-c]quinazolin-5-yl)nicotinamide (available from Axon Medchem); AS-252424(5-[l-[5-(4-fluoro-2-hydroxyphenyl)-furan-2-yl]-meth-(Z)-ylidene]-thiazolidined-2,4-dione (Axon Available from Medchem); TGX-221(7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido-[1,2-a]pyrimidine-4-one (available from Axon Medchem); XL-765;Other PI3K inhibitors include demethoxypyridine, perifosine, CAL101, PX-866, BEZ235, SF1126, INK1117, IPI-145, BKM120, XL147, XL765, Palomid529, GSK1059615, ZSTK474, PWT33597, IC87114, TGI00-115, CAL263, PI-103, GNE-477, CUDC-907, and AEZS-136.

[0179] AKT inhibitors include, but are not limited to, Akt-1-1 (inhibits Aktl) (Barnett et al., Biochem. J. 2005, Vol. 385 (Pt. 2): pp. 399-408); Akt-1-1,2 (inhibits Akl and 2) (Barnett et al., Biochem. J. 2005, Vol. 385 (Pt. 2): pp. 399-408); API-59CJ-Ome (e.g., Jin et al., Br. J. Cancer 2004, Vol. 91: pp. 1808-1812); 1-H-imidazo[4,5-c]pyridinyl compounds (e.g., WO05 / 011700); indole-3-carbinol and its derivatives (e.g., U.S. Patent No. 6,656,963; Sarkar and Li J Examples include Nutr. 2004, Vol. 134 (Supplement 12): pp. 3493-3498); perifosine (e.g., it interferes with Akt membrane localization; Dasmahapatra et al., Clin. Cancer Res. 2004, Vol. 10 (No. 15): pp. 5242-52); phosphatidylinositol ether lipid analogs (e.g., Gills and Dennis Expert. Opin. Investig. Drugs 2004, Vol. 13: pp. 787-97); and trisirivine (TCN or API-2 or NCI identifier: NSC 154020; Yang et al., Cancer Res. 2004, Vol. 64: pp. 4394-4399).

[0180] mTOR inhibitors include, but are not limited to, ATP-competitive mTORC1 / mTORC2 inhibitors, e.g., PI-103, PP242, PP30; Torin1; FKBP12 enhancers; 4H-1-benzopyran-4-one derivatives; and rapamycin (also known as sirolimus) and its derivatives, including: temsirolimus (Torisel®); everolimus (Afinitor®; WO94 / 09010); ridaforolimus (also known as dehorolimus or AP23573); rapalogs such as those disclosed in WO98 / 02441 and WO01 / 14387, e.g., AP23464 and AP23841; 40-(2-hydroxyethyl)rapamycin; 40-[3-hydroxy(hydroxymethyl)methylpropanoate]-rapamycin (also known as CC1779); 40-epi-(tetrazo (tetrazolyt)-rapamycin (also known as ABT578); 32-deoxorapamycin; 16-pentinyloxy-32(S)-dihydrorapamycin (rapanycin); derivatives disclosed in WO05 / 005434; U.S. Patents Nos. 5,258,389, 5,118,677, 5,118,678, 5,100,883, 5,151,413, 5,120,842, and Examples include derivatives disclosed in Patent No. 5,256,790, and WO94 / 090101, WO92 / 05179, WO93 / 111130, WO94 / 02136, WO94 / 02485, WO95 / 14023, WO94 / 02136, WO95 / 16691, WO96 / 41807, WO96 / 41807 and WO2018204416; as well as phosphorus-containing rapamycin derivatives (e.g., WO05 / 016252). In some embodiments, the mTOR inhibitor is a bisteric inhibitor (see e.g., WO2018204416, WO2019212990 and WO2019212991), e.g., RMC-5552.

[0181] Examples of BRAF inhibitors that can be used in combination with the compounds of this disclosure include vemurafenib, dabrafenib, and encorafenib. BRAF may include class 3 BRAF mutations. In some embodiments, the class 3 BRAF mutation is selected from one or more of the following amino acid substitutions in human BRAF: D287H; P367R; V459L; G466V; G466E; G466A; S467L; G469E; N581S; N581I; D594N; D594G; D594A; D594H; F595L; G596D; G596R, and A762E.

[0182] MCL-1 inhibitors include, but are not limited to, AMG-176, MIK665, and S63845. The myelocyte leukemia-1 (MCL-1) protein is one of the important anti-apoptotic members of the B-cell lymphoma-2 (BCL-2) protein family. Overexpression of MCL-1 is closely associated with tumor progression, as well as resistance to targeted therapies, including BCL-2 inhibitors such as ABT-263, as well as conventional chemotherapy.

[0183] In some embodiments, the additional therapeutic agent is an SHP2 inhibitor. SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 has two N-terminal Src homology domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains regulate the intracellular localization and functional regulation of SHP2. The molecule exists in an inactive, autoinhibitory configuration stabilized by a binding network involving residues from both the N-SH2 and PTP domains. Stimulation by cytokines or growth factors acting through receptor tyrosine kinases (RTKs), for example, results in exposure of the catalytic site and enzymatic activation of SHP2.

[0184] SHP2 is involved in signaling via the RAS-mitogenic factor-activated protein kinase (MAPK), JAK-STAT, or phosphoinositol 3-kinase-AKT pathways. Mutations in the PTPN11 gene and subsequent SHP2 have been identified in several human developmental disorders, such as Noonan syndrome and Leopard syndrome, as well as in human cancers, such as juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and breast, lung, and colon cancer. Some of these mutations destabilize the autoinhibitory configuration of SHP2, promoting self-activation or activation by enhanced growth factors. Therefore, SHP2 is a very attractive target for the development of novel therapies for the treatment of various diseases, including cancer. SHP2 inhibitors (e.g., RMC-4550 or SHP099) combined with RAS pathway inhibitors (e.g., MEK inhibitors) have been shown to inhibit the proliferation of several cancer cell lines (e.g., pancreatic, lung, ovarian, and breast cancer) in vitro. Therefore, combination therapy involving SHP2 inhibitors along with RAS pathway inhibitors can be a common strategy for preventing tumor resistance in a wide range of malignancies and can form the basis of a three-combination inhibitor approach with SOS1 inhibitors.

[0185] Non-limiting examples of such SHP2 inhibitors known in the art include Chen et al., Mol Pharmacol. 2006, vol. 70, p. 562; Sarver et al., J. Med. Chem. 2017, vol. 62, p. 1793; Xie et al., J. Med. Chem. 2017, vol. 60, p. 113734; and Igbe et al., Oncotarget, 2017, vol. 8, p. 113734; and PCT applications: WO2015107493; WO2015107494; WO201507495; WO2016203404; WO2016203405; WO2016203406; WO201102244 0;WO2017156397;WO2017079723;WO2017211303;WO2012041524;WO2017211303;WO2019051084 ;WO2017211303;US20160030594;US20110281942;WO2010011666;WO2014113584;WO2014176488 ;WO2017100279;WO2019051469;US8637684;WO2007117699;WO2015003094;WO2005094314;WO2 008124815;WO2009049098;WO2009135000;WO2016191328;WO2016196591;WO2017078499;WO201 Examples include 7210134;WO2018013597;WO2018129402;WO2018130928;WO20181309928;WO2018136264;WO2018136265;WO2018160731;WO2018172984; and WO2010121212, each of which is incorporated by reference herein.

[0186] In some embodiments, the SHP2 inhibitor binds to the active site. In some embodiments, the SHP2 inhibitor is a mixed-type irreversible inhibitor. In some embodiments, the SHP2 inhibitor binds to an allosteric site, such as a non-covalent allosteric inhibitor. In some embodiments, the SHP2 inhibitor is a covalent SHP2 inhibitor, such as an inhibitor that targets the cysteine ​​residue (C333) outside the active site of a phosphatase. In some embodiments, the SHP2 inhibitor is a reversible inhibitor. In some embodiments, the SHP2 inhibitor is an irreversible inhibitor. In some embodiments, the SHP2 inhibitor is SHP099. In some embodiments, the SHP2 inhibitor is TNO155. In some embodiments, the SHP2 inhibitor is RMC-4550. In some embodiments, the SHP2 inhibitor is RCM-4630. In some embodiments, the SHP2 inhibitor is JAB-3068.

[0187] Proteasome inhibitors include, but are not limited to, carfilzomib (Kyprolis®), bortezomib (Velcade®), and oprozomib.

[0188] Immunotherapy includes, but is not limited to, monoclonal antibodies, immunomodulatory imides (IMiDs), GITR agonists, genetically modified T cells (e.g., CAR-T cells), bispecific antibodies (e.g., BiTE), and anti-PD-1, anti-PDL-1, anti-CTLA4, anti-LAGl, and anti-OX40 agents.

[0189] Immunomodulators (IMiDs) are a class of immunomodulatory drugs (drugs that modulate the immune response) that contain an imide group. The IMiD class includes thalidomide and its analogues (lenalidomide, pomalidomide, and apremilast).

[0190] Exemplary anti-PD-1 antibodies and methods for their use are described in Goldberg et al., Blood 2007, Vol. 110 (No. 1): pp. 186-192; Thompson et al., Clin. Cancer Res. 2007, Vol. 13 (No. 6): pp. 1757-1761; and WO06 / 121168 A1, as well as elsewhere in this specification.

[0191] GITR agonists include, but are not limited to, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), e.g., GITR fusion proteins described in U.S. Patent No. 6,111,090, U.S. Patent No. 8,586,023, WO2010 / 003118 and WO2011 / 090754; or e.g., U.S. Patent No. 7,025,962, EP Examples of anti-GITR antibodies include those described in 1947183, U.S. Patent No. 7,812,135, U.S. Patent No. 8,388,967, U.S. Patent No. 8,591,886, U.S. Patent No. 7,618,632, EP1866339, and WO2011 / 028683, WO2013 / 039954, WO05 / 007190, WO07 / 133822, WO05 / 055808, WO99 / 40196, WO01 / 03720, WO99 / 20758, WO06 / 083289, WO05 / 115451, and WO2011 / 051726.

[0192] Another example of therapeutic agents that can be used in combination with the compounds of this disclosure is anti-angiogenic agents. Anti-angiogenic agents include, but are not limited to, chemical compositions, antibodies, antigen-binding domains, radionuclides, and combinations and conjugates thereof, synthesized and prepared in vitro. Anti-angiogenic agents may be agonists, antagonists, allosteric modulators, toxins, or, more commonly, act to inhibit or stimulate their targets (e.g., by activating or inhibiting receptors or enzymes), thereby promoting cell death or halting cell growth. In some embodiments, one or more additional therapeutic agents include anti-angiogenic agents.

[0193] Anti-angiogenic agents can be MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP-9 (matrix-metalloproteinase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors. Non-specific examples of anti-angiogenic agents include rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include arecoxib, valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors include WO96 / 33172, WO96 / 27583, WO98 / 07697, WO98 / 03516, WO98 / 34918, WO98 / 34915, WO98 / 33768, WO98 / 30566, WO90 / 05719, WO99 / 52910, and WO99 / 528. As described in 89, WO99 / 29667, WO99007675, EP0606046, EP0780386, EP1786785, EP1181017, EP0818442, EP1004578 and US20090012085, and U.S. Patents 5,863,949 and 5,861,510. In some embodiments, MMP-2 and MMP-9 inhibitors have little to no activity to inhibit MMP-1. In some embodiments, MMP-2 and MMP-9 inhibitors selectively inhibit either MMP-2 or AMP-9 compared to other matrix-metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Examples of some specific MMP inhibitors include AG-3340, RO32-3555, and RS13-0830.

[0194] Furthermore, representative anti-angiogenic agents include KDR (kinase domain receptor) inhibitors (e.g., antibodies and antigen-binding regions that specifically bind to kinase domain receptors), anti-VEGF agents (e.g., antibodies or antigen-binding regions that specifically bind to VEGF or soluble VEGF receptors or their ligand-binding regions), such as VEGF-TRAP®, and anti-VEGF receptor agents (e.g., antibodies or antigen-binding regions that specifically bind to them), EGFR inhibitors (e.g., antibodies or antigen-binding regions that specifically bind to them), such as Vectibix® (panitumumab) and erlotinib (Tarceva®), anti-Ang1 and anti-Ang2 agents (e.g., antibodies or antigen-binding regions that specifically bind to them or their receptors, such as Tie2 / Tek), and anti-Tie2 kinase inhibitors (e.g., antibodies or antigen-binding regions that specifically bind to them). Other anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (US2003 / 0162712; US6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen-binding domains, or soluble TWEAK receptor antagonists; see US6,727,225), ADAM disintegrin domains that antagonize the binding of integrins to their ligands (US2002 / 0042368), specifically binding anti-eph receptors or anti-ephrin antibodies or Antigen-binding domains (U.S. Patents No. 5,981,245; No. 5,728,813; No. 5,969,110; No. 6,596,852; No. 6,232,447; No. 6,057,124 and their patent family members) and anti-PDGF-BB antagonists (e.g., specifically binding antibodies or antigen-binding domains), as well as antibodies or antigen-binding domains that specifically bind to PDGF-BB ligands, and PDGFR kinase inhibitors (e.g., antibodies or antigen-binding domains that specifically bind to them). Additional anti-angiogenic agents include SD-7784 (Pfizer, USA); silendide (Merck KGaA, Germany, EPO 0770622); pegaptanib octasodium (Gilead Sciences, USA); alpha-statin (BioActa, UK); M-PGA (Celgene, USA, US 5712291);Ilostat (Arriva, USA, US5892112); Emaxanib (Pfizer, USA, US5792783); Batalanib (Novartis, Switzerland); 2-Methoxyestradiol (EntreMed, USA); TLC ELL-12 (Elan, Ireland); Anecoltabeta acetate (Alcon, USA); Alpha-D148 Mab (Amgen, USA); CEP-7055 (Cephalon, USA); Anti-Vn Mab (Crucell, Netherlands), DAC anti-angioplastic agent (ConjuChem, Canada); Angiocidin (InKine Pharmaceutical, USA); KM-2550 (Kyowa Hakko, Japan); SU-0879 (Pfizer, USA); CGP-79787 (Novartis, Switzerland, EP 0970070); ARGENT technology (Ariad, USA); YIGSR-Stealth (Johnson & Johnson, USA); Fibrinogen-E fragment (BioActa, UK); Angiogenesis inhibitor (Trigen, UK); TBC-1635 (Encysive Pharmaceuticals, USA); SC-236 (Pfizer, USA); ABT-567 (Abbott, USA); Metastatin (EntreMed, USA); Maspin (Sosei, Japan); 2-Methoxyestradiol (Oncology Sciences Corporation, USA); ER-68203-00 (IV AX, USA); Benefin (Lane Labs, USA); Tz-93 (Tsumura, Japan); TAN-1120 (Takeda, Japan); FR-111142 (Fujisawa, Japan, JP 02233610); Platelet factor 4 (RepliGen, USA, EP 407122); vascular endothelial growth factor antagonist (Borean, Denmark); bevacizumab (pINN) (Genentech, USA); angiogenesis inhibitor (SUGEN, USA); XL 784 (Exelixis, USA); XL 647 (Exelixis, USA);MAb, alpha-5 beta-3 integrin second generation (Applied Molecular Evolution, USA and Medlmmune, USA); Enzastaurin hydrochloride (Lilly, USA); CEP 7055 (Cephalon, USA and Sanofi-Synthelabo, France); BC 1 (Genoa Institute of Cancer Research, Italy); rBPI 21 and BPI-derived anti-angiogenic agents (XOMA, USA); PI 88 (Progen, Australia); Silengitide (Merck KGaA, Germany; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA); AVE 8062 (Ajinomoto, Japan); AS 1404 (Cancer Research Laboratory, New Zealand); SG 292 (Telios, USA); Endostatin (Boston Children's Hospital, USA); ATN 161 (Attenuon, USA); 2-Methoxyestradiol (Boston Children's Hospital, USA); ZD 6474 (AstraZeneca, UK); ZD 6126 (Angiogene Pharmaceuticals, UK); PPI 2458 (Praecis, USA); AZD 9935 (AstraZeneca, UK); AZD 2171 (AstraZeneca, UK); Batalanib (pINN), (Novartis, Switzerland and Schering AG, Germany); Tissue Factor Pathway Inhibitor (EntreMed, USA); Pegaptanib (Pinn), (Gilead Sciences, USA); Xanthrizole, (Yonsei University, South Korea); Vaccine, gene-based VEGF-2, (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103, (University of California) at San Diego, USA);PX 478 (ProlX, USA); Metastatin (EntreMed, USA); Troponin I (Harvard University, USA); SU 6668 (SUGEN, USA); OXI 4503 (OXiGENE, USA); o-Guanidine (Dimensional Pharmaceuticals, USA); Motupolamine C (British Columbia University, Canada); CDP 791 (Celltech Group, UK); Atiprimod (pINN), (GlaxoSmithKline, UK); E 7820 (Eisai, Japan); CYC 381 (Harvard University, USA); AE 941, (Aeterna, Canada); Vaccine, Angiogenesis (EntreMed, USA); Urokinase Plasminogen Activator Inhibitor (Dendreon, USA); Ogluphanide (pINN), (Melmotte, USA); HIF-1-alpha Inhibitor, (Xenova, UK); CEP 5214, (Cephalon, USA); BAY RES 2622, (Bayer, Germany); Angiocidin (InKine, USA); A6, (Angstrom, USA); KR 31372, (Korea Research Institute of Chemical Technology, South Korea); GW 2286, (GlaxoSmithKline, UK); EHT 0101, (ExonHit, France); CP 868596, (Pfizer, USA); CP 564959, (OSI, USA); CP 547632 (Pfizer, USA); 786034 (GlaxoSmithKline, UK); KRN 633 (Kirin Brewery, Japan); drug delivery system, intraocular, 2-methoxyestradiol; Anguinex (Maastricht University, Netherlands, and Minnesota University, USA); ABT 510 (Abbott, USA); AAL 993 (Novartis, Switzerland); VEGI (ProteomTech, USA); tumor necrosis factor-alpha inhibitor;SU 11248 (Pfizer, USA and SUGEN USA); ABT 518 (Abbott, USA); YH16 (Yantai Rongchang, China); S-3APG (Boston Children's Hospital, USA and EntreMed, USA); MAb, KDR (ImClone Systems, USA); MAb, Alpha 5 Beta (Protein Design, USA); KDR kinase inhibitor (Celltech Group, UK and Johnson & Johnson, USA); GFB 116 (South Florida University, USA and Yale University, USA); CS 706 (Sankyo, Japan); Combretastatin A4 prodrug (Arizona State University, USA); Chondroitinase AC (IBEX, Canada); BAY RES 2690 (Bayer, Germany); AGM 1470 (Harvard University, USA, Takeda, Japan, and TAP, USA); AG 13925 (Agouron, USA); Tetrathiomolybdate (University of Michigan, USA); GCS 100 (Wayne State University, USA); CV 247 (Ivy Medical, UK); CKD 732 (Chong Kun Dang, South Korea); Ilsogladine (Nippon Shinyaku, Japan); RG 13577 (Aventis, France); WX 360 (Wilex, Germany); Squalamine (Genaera, USA); RPI 4610 (Sirna, USA); Heparanase inhibitor (InSight, Israel); KL 3106 (Kolon, South Korea); Honokiol (Emory University, USA); ZK CDK (Schering AG, Germany); ZK Angio (Schering AG, Germany); ZK 229561 (Novartis, Switzerland, and Schering AG, Germany); XMP 300 (XOMA, USA); VGA 1102 (Taisho, Japan); VE-cadherin-2 antagonist (ImClone Systems, USA); Vasostatin (National Institutes of Health, USA); Flk-1 (ImClone Systems, USA); TZ 93 (Tsumura, Japan); Tamstatin (Beth Israel Hospital, USA); Sclerated soluble FLT 1 (vascular endothelial growth factor receptor 1) (Merck & Co, USA); Tie-2 ligand (Regeneron, USA); and thrombospondin 1 inhibitor (Allegheny Examples include the Health, Education and Research Foundation (USA).

[0195] Further examples of therapeutic agents that can be used in combination with the compounds of this disclosure include agents that specifically bind to and inhibit the activity of growth factors (e.g., antibodies, antigen-binding domains, or soluble receptors), such as antagonists of hepatocyte growth factor (HGF, also known as scatter factor), and antibodies or antigen-binding domains that specifically bind to its receptor, c-Met.

[0196] Another example of therapeutic agents that can be used in combination with the compounds of this disclosure is autophagy inhibitors. Autophagy inhibitors include, but are not limited to, chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil®), bafilomycin A1, 5-amino-4-imidazole carboxamidriboside (AICAR), okadaic acid, autophagy-suppressing algal toxins that inhibit type 2A or type 1 protein phosphatases, analogs of cAMP, and drugs that increase cAMP levels, such as adenosine, LY204002, N6-mercaptopurine riboside, and vinblastine. In addition, but are not limited to, antisense or siRNAs that inhibit the expression of proteins including ATG5 (which are involved in autophagy) can also be used. In some embodiments, one or more additional therapeutic agents include autophagy inhibitors.

[0197] Another example of therapeutic agents that can be used in combination with the compounds of this disclosure is antineoplastic agents. In some embodiments, one or more additional therapeutic agents include antineoplastic agents. Non-limiting examples of antineoplastic agents include acemannan, acralubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amiphostin, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, algravin, arsenic trioxide, BAM-002 (Novelos), bexarotene, bicalutamide, proxuridine, capecitabine, cermoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocphosphonate, and DA3030 (Dong-A), daclizumab, denileukin difutitox, deslorerin, dexrazoxane, dilazep, docetaxel, docosanol, doxelcalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alpha, daunorubicin, doxorubicin, tretinoin, ederfosine, edrecolomab, eflornithine, emiteflu, epirubicin, epoetin beta, etoposide phosphate, exemestane, extract Lind, Fadrozol, Filgrastim, Finasteride, Fludarabine Phosphate, Formestan, Hotemustine, Gallium Nitrate, Gemcitabine, Gemtuzumabuzogamicin, Gimeracil / Oteracil / Tegafur Combination, Glycopine, Goserelin, Heptaplatin, Human Chorionic Gonadotropin, Human Fetal Alpha-Fetoprotein, Ibandronic Acid, Idarubicin, (Imiquimod, Interferon Alpha, Interferon Alpha, Natural, Interferon Alpha-2, Interferon Alpha-2a, Interferon Interferon Alpha-2b, Interferon Alpha-Nl, Interferon Alpha-n3, Interferon Alpha-1, Interferon Alpha, Natural, Interferon Beta, Interferon Beta-la, Interferon Beta-lb, Interferon Gamma, Natural Interferon Gamma-la, Interferon Gamma-lb, Interleukin-1 Beta, Yobenguan, Irinotecan, Ilsogladine, Lanreotide, LC9018 (Yakult), Leflunomide, Lenograstim, Lentinansul Phate, Letrozole, Leukocyte Alpha Interferon, Leuprorelin, Levamysol + Fluorouracil, Rialozol, Lovaplatin, Ronidamin, Lovastatin, Masoprocol, Melalsoprole, Metoclopramide, Mifepristone, Miltefosine, Millimostim, Mimatch Double-Stranded RNA, Mitoguazone, Mitractol, Mitoxantrone, Morglamostim, Nafarelin, Naloxone + Pentazocine, Naltograstim, Nedaplatin, Niltamide, Noscapine, Novel Erythrocyte Production Stimulating Protein Preparations, NSC631570 Octreotide, Oprelbequine, Osateron, Oxaliplatin, Paclitaxel, Pamidronic Acid, Pegaspargase, Peginterferon Alpha-2b, Pentosan Sodium Polysulfate, Pentostatin, Picibanil, Pirarubicin, Rabbit Antithymocyte Polyclonal Antibody, Polyethylene Glycol Interferon Alpha-2a, Porfimer Sodium, Raloxifene, Larcitrexed, Rasbrien Bodyment, Rhenium Re186 Etidronate, RII Retinamide, Rituximab, Romultide, Samarium (153Sm) Lexidronam, Salglamostim, Schizophyllan, Sobuzoxan, Sonel Min, strontium-89 chloride, suramin, tasonelmin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, simalfasin, thyrotropin alpha, topotecan, toremifene, tositumomab-iodine-131, trastuzumab, treosulfan, tretinoin, trilostane, trimethrexate, triptorelin, natural tumor necrosis factor alpha, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, barrubicin, verteporfin, vinorelbine, bilirudin, dinostatin stimalamer or zoledronic acid; abalelix; AE 941 (Aeterna), Ambamustine, Antisense oligonucleotide, bcl-2 (Genta), APC 8015 (Dendreon), Decitabine, Dexaminoglutethimide, Diadicon, EL 532 (Elan), EM 800 (Endorecherche), Enyluracil, Etanidazole, Fenretinide, Filgrastim SD01 (Amgen), Fulvestrant, Gallocitabine, Gastrin 17 immunogen, HLA-B7 gene therapy (Vical), Granulocyte-macrophage colony-stimulating factor, Histamine dihydrochloride, Ibritumomab tiuxetan, Ilostat, IM862 (Cytran), Interleukin-2, Iproxyfen, LDI200 (Milk House), Religistim, Lintuzumab, CA 125 MAb (Biomira), Cancer MAb (Japan Pharmaceutical) Development), HER-2 and FcMAb (Medarex), Idiotype 105AD7 MAb (CRC Technology), Idiotype CEA MAb (Trilex), LYM-1-Iodine-131 MAb (Techni clone), Pleuromorphic epithelial mucin-yttrium-90 MAb (Antisoma), Marimast, Menogalil, Mitsumomab, Motexafingadolinium, MX 6 (Galderma), Nelarabine, Noratexed, P30 protein, Pegvisomant, Pemetrexed, Porphyromycin, Prinomast, RL 0903 (Shire), Rubitecan, Satraplatin, Sodium phenylacetate, Sparfos acid, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA Examples include 077 (Tanabe), tetrathiomolybdate, taliblastine, thrombopoietin, ethyl etioplurils, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering Institute), melanoma oncolysate vaccine (New York Medical College), melanoma cell virus lysate vaccine (Royal Newcastle Hospital), or valspodar.

[0198] Additional examples of therapeutic agents that can be used in combination with the compounds of this disclosure include ipilimumab (Yervoy®); tremelimumab; galiximab; nivolumab, also known as BMS-936558 (Opdivo®); pembrolizumab (Keytruda®); avelumab (Bavencio®); AMP224; BMS-936559; MPDL3280A, also known as RG7446; MEDI-570; AMG557; MGA271; IMP321; BMS-663513; PF-05082566; CDX-1127; anti-OX40 (Providence Health) Services); huMAbOX40L; Atasicept; CP-870893; Lucatumumab; Dasetuzumab; Muromonab-CD3; Ipilumumab; MEDI4736 (Imfinzi®); MSB0010718C; AMP 224; Adalimumab (Humira®); ado-trastuzumab emtansine (Kadcyla®); Aflibercept (Eylea®); Alemtuzumab (Campath®); Basiliximab (Simulect®); Belimumab (Benlysta®); Basiliximab (Simulect®); Belimumab (Benlysta®); Brentuximab Vedotin (Adcetris®); Canakinumab (Ilaris®); Certolizumab pegol (Cimzia®); Daclizumab (Zenapax®); Daratumumab (Darzalex®); Denosumab (Prolia®); Eculizumab (Soliris®); Ephalizumab (Raptiva®); Gemtuzumab Ozogamicin (Mylotarg®); Golimumab (Simponi®); Ibritumomab tiuxetan (Zevalin®); Infliximab (Remicade®); Motabizumab (Numax®); Natalizumab (Tysabri®); Obinutuzumab (Gazyva®); Ofatumumab (Arzerra®); Omalizumab (Xolair®);Examples include palivizumab (Synagis®); pertuzumab (Perjeta®); pertuzumab (Perjeta®); ranibizumab (Lucentis®); laxibakumab (Abthrax®); tocilizumab (Actemra®); tositumomab; tositumomab-i-131; tositumomab and tositumomab-i-131 (Bexxar®); ustekinumab (Stelara®); AMG 102; AMG 386; AMG 479; AMG 655; AMG 706; AMG 745; and AMG 951.

[0199] In some embodiments, additional compounds used in combination therapy with the compounds of the Disclosure are selected from the group consisting of CDK4 / 6 inhibitors (e.g., abemaciclib, palbociclib, or ribociclib), KRAS:GDPG12C inhibitors (e.g., AMG510, MRTX1257) or other mutant Ras:GDP inhibitors, KRAS:GTPG12C inhibitors or other mutant Ras:GTP inhibitors, MEK inhibitors (e.g., refametinib, selumetinib, trametinib, or cobimetinib), SHP2 inhibitors (e.g., TNO155, RMC-4630), ERK inhibitors, and RTK inhibitors (e.g., EGFR inhibitors).

[0200] In some embodiments, additional compounds used in combination therapy with the compounds of the Disclosure are selected from the group consisting of ABT-737, AT-7519, carfilzomib, cobimetinib, danucertib, dasatinib, doxorubicin, GSK-343, JQ1, MLN-7243, NVP-ADW742, paclitaxel, palbociclib, and boracertib. In some embodiments, additional compounds used in combination therapy with the compounds of the Disclosure are selected from the group consisting of neratinib, acetinib, and reversin.

[0201] The compounds described herein can be used in combination with the agents disclosed herein or other suitable agents, depending on the condition being treated. Therefore, in some embodiments, one or more compounds of this disclosure are administered concurrently with other treatments as described herein. When used in combination therapy, the compounds described herein may be administered concurrently or separately with a second agent. Combination administrations include concurrent administration of two agents in the same dosage form, concurrent administration of different dosage forms, and separate administrations. That is, either the compounds described herein or the agents described herein can be formulated together in the same dosage form and administered concurrently. Alternatively, the compounds of this disclosure and any of the treatments described herein can be administered concurrently, where both agents are in separate formulations. As another alternative, the compounds of this disclosure may be administered followed by any of the treatments described herein, or vice versa. In some embodiments of separate administration protocols, the compounds of this disclosure and any of the treatments described herein are administered with intervals of several minutes, several hours, or several days.

[0202] In some embodiments, the combination therapy regimen employs two therapeutic agents, one of which is selected from the compounds of this disclosure and the second from the therapeutic agents described herein. In some embodiments, the combination therapy regimen employs three therapeutic agents, one of which is selected from the compounds of this disclosure and the second from the therapeutic agents described herein. In some embodiments, the combination therapy regimen employs four or more therapeutic agents, one of which is selected from the compounds of this disclosure and the third from the therapeutic agents described herein.

[0203] In some embodiments of any of the methods described herein, the first treatment (e.g., the compounds of this disclosure) and one or more additional treatments are administered simultaneously or sequentially in any order. The first treatment agent may be administered immediately before or after one or more additional treatments for up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to 16 hours, up to 17 hours, up to 18 hours, up to 19 hours, up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours, up to 24 hours, or up to 1-7, 1-14, 1-21 or 1-30 days.

[0204] In this section, all references to the listed medications, whether explicitly stated or not, are incorporated by reference. 6. Kit Another aspect of the present disclosure provides a kit comprising a compound of any one of the above formulas, or a pharmaceutical composition comprising a compound of any one of the above formulas of the present disclosure. The kit may also comprise a diagnostic or therapeutic agent in addition to a compound of any one of the above formulas of the present disclosure or its pharmaceutical composition. The kit may also comprise instructions for use in a diagnostic or therapeutic setting. In some embodiments, the kit comprises a compound of any one of the above formulas or its pharmaceutical composition, and a diagnostic agent. In other embodiments, the kit comprises a compound of any one of the above formulas or its pharmaceutical composition.

[0205] In yet another embodiment, the Disclosure includes a kit suitable for use in carrying out the methods of treatment described herein. In one embodiment, the kit includes a first dosage form containing one or more of the compounds of the Disclosure in an amount sufficient to carry out the method of the Disclosure. In another embodiment, the kit includes one or more of the compounds of the Disclosure in an amount sufficient to carry out the method of the Disclosure, and a container for administration and a container for administration. 7. Preparation Any one of the compounds of the above formulas can be prepared by the general and specific methods described below using the ordinary general knowledge of those skilled in the art of synthetic organic chemistry. Such ordinary general knowledge can be found in standard references, such as Comprehensive Organic Chemistry, edited by Barton and Ollis, Elsevier; Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Larock, John Wiley and Sons; and Compendium of Organic Synthetic Methods, Volumes I-XII (published by Wiley-Interscience). The starting materials used herein can be commercially available or prepared by customary methods known in the art.

[0206] It should be noted that in the preparation of any one of the compounds of the above formulas, some of the preparation methods described herein may require protection of remote functional groups (e.g., primary amines, secondary amines, or carboxyls in any one of the above precursor formulas). The need for such protection varies depending on the nature of the remote functional group and the conditions of the preparation method. The need for such protection is readily determined by those skilled in the art. The use of such protection / deprotection methods is also within the realm of the art. For a general description of protecting groups and their uses, see Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

[0207] For example, certain compounds contain primary amine or carboxylic acid functionalities that, if left unprotected, may interfere with reactions at other parts of the molecule. Therefore, such functionalities can be protected by suitable protecting groups that can be removed in subsequent steps. Suitable protecting groups for amine and carboxylic acid protections are generally chemically inactive under the reaction conditions described and can typically remove other functionalities in any one of the above compound formulas without chemically altering them. These are commonly used protecting groups in peptide synthesis (e.g., Nt-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-fluorenylmethyleneoxycarbonyl (Fmoc) for amines, and lower alkyl or benzyl esters for carboxylic acids).

[0208] The following scheme is intended to provide a general description of the methodology employed in the preparation of the compounds of this disclosure. Some of the compounds of this disclosure may contain one or more chiral centers having stereochemical names (R) or (S). It will be apparent to those skilled in the art that all synthetic transformations can be carried out in similar manner, regardless of whether the material is enantio-rich or racemic. Furthermore, the resolution of the desired optically active material can be carried out at any desired point in the sequence using methods such as those described herein and those well known in the chemical literature. [Examples]

[0209] Abbreviation: Argon DAST Diethylaminosulfur Trifluoride DCM Dichloromethane DIEA N,N-diisopropylethylamine DMF (N,N-dimethylformamide) DMF-DMA N,N-dimethylformamide dimethylacetal DMSO (Dimethyl Sulfoxide) Dppf 1,1'-bis(diphenylphosphino)ferrocene EA ethyl acetate EtOH Ethanol HCl ethyl acetate HATU N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridine-1-ylmethylene]-N methylmethaneaminium hexafluorophosphate N-oxide HPLC (High-Performance Liquid Chromatography) i-PrOH Isopropyl Alcohol LC-MS (Liquid Chromatography-Mass Spectrometry) MeOH methanol Pd(dppf)Cl2 dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium Pd(PPh3)4Tetrakis(triphenylphosphine)palladium PE (Petroleum Ether) TEA (Triethylamine) THF (Tetrahydrofuran) Tf Triflate Ts Tosil Xantphos 4,5-bis(diphenylphosphin)-9,9-dimethylxanthene Synthesis Example 1. Synthesis process for preparing the intermediate. Intermediate 1

[0210] [ka]

[0211] Step 1: To a stirred solution of 2-MeTHF (75 mL), dimethyl 3-oxopentanedioate (10 g, 57.4 mmol) and DMF-DMA (6.8 g, 57.4 mmol) were added at 4°C. The mixture was stirred for 3 hours. The reaction mixture was warmed to room temperature, and aqueous hydrochloric acid (4N, 26 mL) was slowly added. After stirring at room temperature for 3 hours, the organic layer was separated, washed with water (20 mL) and brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain dimethyl 2-formyl-3-oxopentanediate (11 g, 95% yield) as a pale yellow liquid, which was used directly without further purification. LC-MS: m / z 202.9 [M+H] + .

[0212] Step 2: A mixture of dimethyl 2-formyl-3-oxopentanediote (2.3 g, 11.5 mmol) and morpholine-4-amine (1.1 g, 10.4 mmol) in MeOH (15 mL) was stirred at room temperature for 12 hours. MeONa (647.9 mg, 12.0 mmol) was added to the mixture and stirred for 6 hours. The mixture was quenched with H2O (15 mL) and acidified to pH 1-2 with aq. HCl (1N). The resulting solid was filtered, washed with MeOH and H2O (1:1, V:V), and dried under vacuum to obtain methyl 4-hydroxy-1-morpholino-6-oxopyridine-3-carboxylate as a white solid (2 g, 75% yield). LC-MS: m / z 254.9 [M+H] + .

[0213] Step 3: 4-methylbenzenesulfonyl chloride (1.5 g, 7.9 mmol) was added to a stirred solution of methyl 4-hydroxy-1-morpholino-6-oxopyridine-3-carboxylate (2.0 g, 7.9 mmol) and TEA (1.2 g, 11.8 mmol) in CH3CN (50 mL). The mixture was stirred at room temperature for 1 hour. The resulting solid was filtered and washed with CH3CN to obtain methyl 1-morpholino-6-oxo-4-(p-tolylsulfonyloxy)pyridine-3-carboxylate (2.6 g, 81% yield). LC-MS: m / z 408.8 [M+H] + .

[0214] Step 4: A mixture of methyl 1-morpholino-6-oxo-4-(p-tolylsulfonyloxy)pyridine-3-carboxylate (2.0 g, 5.0 mmol), acetamide (590.1 mg, 10 mmol), palladium (π-cinnamyl) chloride dimer (129.4 mg, 249.7 μmol), XantPhos (289.2 mg, 499.5 μmol), and K3PO4 (2.7 g, 12.5 mmol) in dioxane (50 mL) was stirred at 100 °C for 12 hours. The mixture was purified by flash column chromatography to obtain methyl 4-acetamido-1-morpholino-6-oxopyridine-3-carboxylate (1.0 g, yield 68%). LC-MS: m / z 295.9 [M+H] + .

[0215] Step 5: A mixture of methyl-4-acetamido-1-morpholino-6-oxopyridine-3-carboxylate (295 mg, 1.0 mmol) and a solution of NH3 in MeOH (7 M, 5 mL) was heated at 60°C for 16 hours. The mixture was concentrated and filtered to obtain 2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (200 mg, 76% yield), which was used in the next step without further purification. LC-MS: m / z 262.9 [M+H] + .

[0216] Additional intermediates of this disclosure were prepared using the corresponding derivatives, in a manner similar to the representative procedure described for Intermediate 1. The selected compounds and their corresponding characterization data are shown in the table below.

[0217] [Table 2-1]

[0218] [Table 2-2]

[0219] Intermediate 10

[0220] [ka]

[0221] Step 1: To a solution of (2S,6R)-2,6-dimethylmorpholine (2.0 g, 17.4 mmol) in water (25 mL), sodium nitrite (1.8 g, 26.1 mmol) and acetic acid (1.4 g, 22.5 mmol) at 0°C were added. The mixture was stirred at 20°C for 2 hours. The mixture was diluted with CH2Cl2 (80 mL) and then washed with aq.NaHCO3 (30 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to obtain (2S,6R)-2,6-dimethyl-4-nitrosomorpholine as a yellow oil (2.5 g, 99% yield).

[0222] Step 2: To a solution of (2S,6R)-2,6-dimethyl-4-nitrosomorpholine (2.5 g, 17.4 mmol) in CH3OH (25 mL), acetic acid (3.1 g, 52.1 mmol) and zinc (3.4 g, 52.1 mmol) at 0°C were added. The mixture was stirred at 20°C for 4 hours. The mixture was filtered, and the filtrate was concentrated to obtain (2S,6R)-2,6-dimethylmorpholine-4amine (7 g) as a white solid.

[0223] The following compounds were prepared in the same manner as the typical procedure described for intermediate 10.

[0224] [Table 3]

[0225] Intermediate 15

[0226] [ka]

[0227] A mixture of 2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (26.2 mg, 99.9 μmol) and 1-bromopyrrolidine-2,5-dione (17.8 mg, 99.9 μmol) in CH3CN (2 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated and washed with MeOH (5 mL) to obtain 8-bromo-2-methyl-6-morpholinopyrido[4,3-d]pyrimidine-4,7(3H,6H)-dione (25 mg). LC-MS: m / z 341.7 [M+H] + .

[0228] Intermediate 16

[0229] [ka]

[0230] Step 1: To a solution of 5-bromobenzene-1,3-dicarboxyl (5 g, 23.5 mmol) in CH2Cl2 (70 mL), DAST (22.7 g, 140.8 mmol) at 0°C was slowly added. The mixture was stirred at 20°C for 8 hours. The solution was poured onto ice (120 mL) and saturated sodium bicarbonate (100 mL) was added. The mixture was extracted with CH2Cl2 (3 × 200 mL). The organic layers were combined, dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain 1-bromo-3,5-bis(difluoromethyl)benzene (3.8 g, yield 63%) as a colorless oil.

[0231] Step 2: A solution of 1-vinyloxybutane (779.3 mg, 7.7 mmol), 1-bromo-3,5-bis(difluoromethyl)benzene (1 g, 3.9 mmol), Pd(OAc)2 (87.3 mg, 389.1 μmol), potassium phosphate (1.6 g, 7.7 mmol), and dppf (431.4 mg, 778.1 μmol) in n-BuOH (15 mL) was mixed with LiOTf (606.9 mg, 3.9 mmol). The mixture was degassed three times with a stream of N2. The mixture was stirred at 110 °C for 16 hours. The mixture was purified by silica gel column chromatography to obtain a colorless oil. The oil was then dissolved in HCl (5 mL) and HCl / HCl (5 mL) was added. The mixture was stirred at 20 °C for 1 hour. The mixture was concentrated and purified by silica gel column chromatography to obtain 1-[3,5-bis(difluoromethyl)phenyl]ethanone as a white solid (260 mg, 30% yield).

[0232] Step 3: To a solution of 1-[3,5-bis(difluoromethyl)phenyl]ethanone (260 mg, 1.2 mmol) and 2-methylpropane-2-sulfinamide (286.2 mg, 2.4 mmol) in THF (8 mL), Ti(OEt)4 (538.7 mg, 2.4 mmol) was added. The mixture was stirred at 80°C for 16 hours. The reaction mixture was diluted with THF (50 mL) and then quenched with water. The mixture was filtered, the filtrate was dried over Na2SO4, filtered, and concentrated to obtain N-[1-[3,5-bis(difluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (400 mg) as a yellow solid, which was used directly in the next step without further purification.

[0233] Step 4: To a solution of N-[1-[3,5-bis(difluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (400 mg, 1.2 mmol) in THF (8 mL), NaBH4 (140.4 mg, 3.7 mmol) was added. The mixture was stirred at 0°C for 2 hours. The reaction mixture was quenched with water. The mixture was extracted with ELISA (2 × 50 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to obtain N-[1-[3,5-bis(difluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (400 mg, 99% yield) as a yellow solid.

[0234] Step 5: A solution of N-[1-[3,5-bis(difluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (400 mg, 1.2 mmol) in HCl / Depositphotos (8 mL, 4N) was stirred at 20°C for 16 hours. The reaction mixture was concentrated. The residue was suspended in Depositphotos (50 mL) and washed with aq.NaHCO3 (25 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to obtain 1-[3,5-bis(difluoromethyl)phenyl]ethaneamine as an oil (150 mg, yield 55%).

[0235] Intermediate 17

[0236] [ka]

[0237] Step 1: To a solution of 3-bromo-2-fluorobenzaldehyde (200 g, 956 mmol) in dichloromethane (3000 mL) under N2 conditions, DAST (308 g, 1912 mmol) was added at 0°C, and the mixture was stirred at 0°C for 1 hour. The mixture was then warmed to room temperature and stirred for 1 hour. The reaction product was carefully quenched with saturated sodium bicarbonate solution. The reaction product was then diluted with ethyl acetate (3000 mL), the organic layer was washed with saturated sodium bicarbonate solution and brine, then concentrated to dryness, and purified by chromatography (0-50% ethyl acetate in PE, 20 min) to obtain l-bromo-3-(difluoromethyl)-2-fluorobenzene as an oil (135 g, yield 61%).

[0238] Step 2: l-bromo-3-(difluoromethyl)-2-fluorobenzene (125 g, 556 mmol) was dissolved in anhydrous 1,4-dioxane (1.2 L). Triethylamine (140 mL, 1389 mmol) and tributyl(1-ethoxyvinyl)tin (241 g, 667 mmol) were added, and the resulting solution was purged with argon for 15 minutes. Bis(triphenylphosphine)palladium(II) chloride (3.9 g, 5.6 mmol) was added. The reaction mixture was heated in an autoclave at 100°C for 16 hours. After the transformation of the starting materials was complete, the reaction mixture was cooled to room temperature, treated with 1N HCl, and stirred for a further 16 hours. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered, and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography (SiO2, hexane / ethyl acetate 10:1) to obtain 1-(3-(difluoromethyl)-2-fluorophenyl)ethanone (78 g, 76% yield). LC-MS: m / z 189.0 [M+H] + .

[0239] Step 3: 1-(3-(difluoromethyl)-2-fluorophenyl)ethanone (70 g, 372 mmol) was dissolved in THF (1.0 L). (R)-(+)-2-methyl-2-propanesulfinamide (68.3 g, 564 mmol) and titanium tetraethoxide (257.5 g, 1129 mmol) were added at room temperature. The resulting reaction mixture was heated at 80°C for 16 hours. After the transformation of the starting materials was complete, ice water and SiO were added, and the aqueous layer was extracted with SiO. The organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure to obtain (R,E)-N-(1-(3-(difluoromethyl)-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide, which was used in the next step without further purification. LC-MS: m / z 292.0[M+H] + .

[0240] Step 4: A solution of (R,E)-N-(1-(3-(difluoromethyl)-2-fluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide (100 g, 343.6 mmol) was dissolved in THF (1.2 L) and cooled to 0°C. Sodium borohydride (12.7 g, 343.2 mmol) was added, and the resulting reaction mixture was stirred at room temperature for 6 hours. After the transformation of the starting materials was complete, ice water and SiO were added. The aqueous layers were extracted with SiO, combined, dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by chromatography (gradient elution: 33% ethyl acetate in petroleum ether), and isomer 1: (R)-N-((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide was obtained as a yellow oil, LC-MS: m / z 294.0[M+H]+ (65g, yield 64%); isomer 2: (R)-N-((S)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide was obtained as a yellow oil, LC-MS: m / z 294.0[M+H] + It was obtained as such.

[0241] Step 5: To a solution of (R)-N-((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (65 g, 221.8 mmol) in EA (600 mL), 4N HCl in dioxane (300 mL) was added and the mixture was stirred for 1.5 hours at room temperature under N2. After the reaction was complete, the solution was removed under vacuum, the solid was collected, and diluted with water. The mixture was adjusted to pH=8 with aq.NaHCO3 and extracted with EA (3 × 300 mL). The combined organic layer was concentrated to obtain (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine as a pale yellow oil (31 g, yield 73%). LC-MS: m / z 191.1 [M+H] + ee value = 99%, RT = 0.88 min (column: Cellulose-SC, 4.6 × 100 mm, 5 μm).

[0242] (S)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine was prepared using (R)-N-((S)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide as the starting material, following the same procedure. LC-MS: m / z 191.1[M+H] + Room temperature = 1.12 min (Column: Cellulose-SC, 4.6 × 100 mm, 5 μm).

[0243] Synthesis Example 2. Synthesis process for preparing the illustrated compound Synthesis Examples Example 1

[0244] [ka]

[0245] To a stirred solution of 2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (52.4 mg, 199.8 μmol) in CH3CN (10 mL), K3PO4 (105.9 mg, 499.5 μmol) and 2,2,4,4,6,6-hexachloro-1,3,5-triaza-2,4,6-triphosphacyclohexa-1,3,5-triene (69.5 mg, 199.8 μmol) were added. The mixture was stirred at room temperature for 2 hours. (1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethaneamine (37.8 mg, 199.8 μmol) was added, and the mixture was stirred for 2 hours. The reaction mixture was concentrated and purified by prep-HPLC to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (20 mg, yield 24%). LC-MS: m / z 433.8[M+H] + .

[0246] The following compounds were prepared in the same manner as the typical procedure described for Example 1.

[0247] [Table 4-1]

[0248] [Table 4-2]

[0249] Example 10

[0250] [ka]

[0251] A solution of tert-butyl 4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-7-oxopyrido[4,3-d]pyrimidine-6-yl]piperazine-1-carboxylate (500 mg, 938.8 μmol) (4N) in HCl / HCl (10 mL) was stirred at 20°C for 1.5 hours. The mixture was concentrated and purified by prep-HPLC to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-piperazine-1-yl-pyrimidine-7-one as a pale yellow solid (110 mg, yield 27%). LC-MS: m / z 432.8[M+H] + .

[0252] Example 11

[0253] [ka]

[0254] To a solution of 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-piperazine-1-ylpyrido[4,3-d]pyrimidine-7-one (60 mg, 127.9 μmol) in CH2Cl2 (4 mL), TEA (38.8 mg, 383.8 μmol) and acetyl chloride (10.0 mg, 127.9 μmol) at 0°C were added. The mixture was stirred at 0°C for 2 hours. The mixture was diluted with CH2Cl2 (50 mL) and then washed with brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain 6-(4-acetylpiperazin-1-yl)-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methylpyrido[4,3-d]pyrimidine-7-one (14.1 mg, yield 23%). LC-MS: m / z 474.8[M+H] + .

[0255] Example 12

[0256] [ka]

[0257] A solution of 2-iodopropane (39.9 mg, 234.8 μmol), potassium carbonate (40.6 mg, 293.5 μmol), and 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-6-(4-isopropylpiperazin-1-yl)-2-methylpyrido[4,3-d]pyrimidine-7-one (60 mg, 117.4 μmol) in DMF (3 mL) was stirred at 40°C for 16 hours. The mixture was diluted with HCl (100 mL) and then washed with brine (3 × 320 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-6-(4-isopropylpiperazin-1-yl)-2-methylpyrido[4,3-d]pyrimidine-7-one (1.9 mg, yield 3%) as a pale yellow solid. LC-MS: m / z 474.9[M+H] + .

[0258] Example 13

[0259] [ka]

[0260] HATU (73.4 mg, 191.9 μmol) was added to a solution of 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-piperazine-1-ylpyrido[4,3-d]pyrimidine-7-one (60 mg, 127.9 μmol), TEA (38.8 mg, 383.9 μmol), and 2-hydroxyacetic acid (9.7 mg, 127.9 μmol) in DMF (3 mL). The mixture was stirred at 20°C for 2 hours. The mixture was diluted with SiO (100 mL) and then washed with brine (3 × 20 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-6-[4-(2-hydroxyacetyl)piperazin-1-yl]-2-methylpyrido[4,3-d]pyrimidine-7-one as a pale yellow solid (2.1 mg, yield 3%). LC-MS: m / z 490.8[M+H] + .

[0261] The following compounds were prepared in the same manner as the typical procedure described for Example 13.

[0262] [Table 5]

[0263] Example 15

[0264] [ka]

[0265] A solution of 6-fluoropyridine-3-carbonitride (28.6 mg, 234.8 μmol), NaHCO3 (16.7 mg, 199.6 μmol), and 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-piperazine-1-ylpyrido[4,3-d]pyrimidine-7-one (50.7 mg, 117.4 μmol) in DMSO (3 mL) was stirred at 100 °C for 6 hours. The mixture was diluted with HCl (100 mL) and then washed with brine (3 × 20 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain 6-[4-[4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-7-oxopyrido[4,3-d]pyrimidine-6-yl]piperazin-1-yl]pyridine-3-carbonitrile as a pale yellow solid (2 mg, yield 3%). LC-MS: m / z 534.8[M+H] + .

[0266] Example 16

[0267] [ka]

[0268] Step 1: To a stirred solution of 2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (100 mg, 381.3 μmol) and K3PO4 (202.1 mg, 953.2 μmol) in CH3CN (15 mL), phosphonitrile chloride trimer (132.7 mg, 381.3 μmol) was added. The mixture was stirred at room temperature for 2 hours. (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine (89.3 mg, 381.3 μmol) was added. The mixture was stirred for 2 hours. The reaction mixture was concentrated and purified by flash column chromatography to obtain 2-methyl-6-morpholino-4-[[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]amino]pyrido[4,3-d]pyrimidine-7-one (50 mg, 27% yield). LC-MS: m / z 478.8 [M+H] + .

[0269] Step 2: A mixture of 2-methyl-6-morpholino-4-[[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]amino]pyrido[4,3-d]pyrimidine-7-one (10 mg, 20.9 μmol), iron (5.8 mg, 104.5 μmol), and NH4Cl (11.2 mg, 209.0 μmol) in EtOH (2 mL) and H2O (2 mL) was stirred at 75°C for 3 hours. The reaction mixture was concentrated and purified by prep-HPLC to obtain 4-[[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (2 mg, yield 21%). LC-MS: m / z 448.8[M+H] + .

[0270] Example 17

[0271] [ka]

[0272] A mixture of 2-methyl-6-morpholinopyrido[4,3-d]pyrimidine-4,7(3H,6H)-dione (52.4 mg, 0.2 mmol), K3PO4 (106 mg, 0.5 mmol), and a phosphonitrile chloride trimer (70 mg, 0.2 mmol) in CH3CN (10 mL) was stirred at room temperature for 3 hours. (R)-1-(2-methyl-3-(trifluoromethyl)phenyl)ethane-1-amine (45 mg, 0.22 mmol) was added. The mixture was stirred at 80°C for 2 hours. The solvent was removed. DCM (100 mL) and water (20 mL) were added. The mixture was stirred for 20 minutes. The organic phase was dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain (R)-2-methyl-4-((1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)amino)-6-morpholinopyrid[4,3-d]pyrimidine-7(6H)-one (15 mg). LC-MS: m / z 447.8[M+H] + .

[0273] The following compounds were prepared in the same manner as the typical procedure described for Example 17.

[0274] [Table 6-1]

[0275] [Table 6-2]

[0276] [Table 6-3]

[0277] Example 29

[0278] [ka]

[0279] Step 1: To a stirred solution of 4,6-dichloro-2-methylpyrimidine-5-carbaldehyde (5.0 g, 26 mmol) in toluene (150 mL), ethylene glycol (8.0 g, 131.0 mmol) and TsOH (0.5 g, 2.5 mmol) were added. The reaction mixture was refluxed in a water segregator until complete conversion of the starting materials was observed. The solvent was evaporated under reduced pressure. The residue was diluted with DCM (150 mL) and washed with aqueous sodium bicarbonate solution. The organic layers were combined, dried over Na₂SO₄, concentrated under reduced pressure, and purified by flash column chromatography to obtain 4,6-dichloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine (4.0 g). LC-MS: m / z 457.2 [M+H] + .

[0280] Step 2: A mixture of 4,6-dichloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine (1.5 g, 6.4 mmol), dimethyl 2-fluoromalonate (960 mg, 6.4 mmol), and Cs2CO3 (2.1 g, 6.4 mmol) in DMF was stirred at 0°C for 1 hour. The mixture was diluted with ELISA (200 mL) and H2O (30 mL). The mixture was stirred at room temperature for 10 minutes. The organic phase was washed with water (3 × 200 mL), dried over Na2SO4, filtered, and concentrated to obtain the crude product, which was purified by column chromatography to obtain dimethyl 2-(6-chloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoromalonate (1.2 g). LC-MS: m / z 348.8 [M + H] + .

[0281] Step 3: A mixture of dimethyl 2-(6-chloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoromalonate (370 mg, 1.1 mmol), (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine (200 mg, 1.1 mmol), and DIEA (410 mg, 3.2 mmol) in DMF was stirred at 80°C for 5 hours. The mixture was diluted with ELISA (100 mL) and H2O (20 mL). The mixture was stirred at room temperature for 10 minutes. The organic phase was washed with water (3 × 200 mL), dried over Na₂SO₄, filtered, and concentrated to obtain the crude product. This crude product was purified by column chromatography to obtain dimethyl(R)-2-(6-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoromalonate (400 mg). LC-MS: m / z 501.8 [M+H] + .

[0282] Step 4: Dimethyl(R)-2-(6-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoromalonate (320 mg, 0.6 mmol) was dissolved in DMSO (5 mL). A 20% aqueous sodium hydroxide solution (384 mg) was added, and the resulting mixture was stirred for 1 hour until complete conversion of the starting materials was observed. Triethylamine (130 mg, 1.3 mmol), morpholine-4-amine (85 mg, 0.8 mmol), and HATU (360 mg, 1.5 mmol) were added, and the resulting mixture was stirred for 1 hour. Water was added, and the mixture was diluted with DCM. The aqueous layer was extracted with DCM. The organic layers were combined, dried over magnesium sulfate, filtered, and concentrated to obtain the crude product, which was purified by column chromatography to obtain 2-(6-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoro-N-morpholinoacetamide (260 mg). LC-MS: m / z 513.8 [M+H] + .

[0283] Step 5: 2-(6-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)-2-fluoro-N-morpholinoacetamide (50 mg, 0.1 mmol) was dissolved in 2 mL of 2-propanol. 100 μL, 0.5 mmol of 5 N aqueous HCl was added, and the resulting mixture was stirred at 50°C for 1 hour until complete conversion of the starting materials was observed. The solvent was removed to obtain the crude product, which was purified by prep-HPLC to obtain (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-8-fluoro-2-methyl-6-morpholinopyrido[4,3-d]pyrimidine-7(6H)-one (20 mg). LC-MS: m / z 451.8 [M+H] + .

[0284] The following compounds were prepared in the same manner as the typical procedure described for Example 29.

[0285] [Table 7]

[0286] Example 34

[0287] [ka]

[0288] Step 1: A solution of diethylpropanediate (613.2 mg, 3.8 mmol) in THF (15 mL) was mixed with 0°C NaH (122.2 mg, 2.5 mmol, 48%). The mixture was stirred at 0°C for 0.5 hours. Next, 4,6-dichloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine (600 mg, 2.5 mmol) was added. The mixture was stirred at 20°C for 10 hours. The reaction mixture was quenched with aq.NH4Cl (20 mL). The mixture was extracted with RINKAN (3 × 35 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain diethyl 2-[6-chloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]propanedioate as a pale yellow solid (220 mg, yield 24%).

[0289] Step 2: (1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethanamine (116 mg, 613.2 μmol) was added to a solution of diethyl 2-[6-chloro-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]propanediolate (220 mg, 613.2 μmol) and CsF (186.3 mg, 1.23 mmol) in DMSO (6 mL). The mixture was stirred at 120 °C for 5 hours. The mixture was diluted with ELISA (60 mL) and then washed with brine (4 × 20 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain diethyl 2-[6-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]propanedioate as a pale yellow solid (110 mg, yield 35%).

[0290] Step 3: To a solution of diethyl 2-[6-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]propanedioate (70 mg, 136.8 μmol) in water (0.5 mL) and ethanol (2 mL), sodium hydroxide (82.1 mg, 410.5 μmol, 20%) was added. The mixture was stirred at 100 °C for 2 hours. The mixture was concentrated. CH3OH (4 mL) was added, and the mixture was filtered. The filtrate was concentrated to obtain (R)-2-(6-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)acetic acid (100 mg) as a yellow solid, which was used directly in the next step without further purification.

[0291] Step 4: To a solution of (R)-2-(6-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl)acetic acid (30 mg, 69 μmol)TEA (17.8 mg, 138.1 μmol) and HATU (52.8 mg, 138.1 μmol) in DMF (1.5 mL), isopropylhydrazine (15.3 mg, 138.1 μmol) was added. The mixture was stirred at 20°C for 0.5 hours. The mixture was diluted with HCl (60 mL) and then washed with brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to obtain 2-[6-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]-N',N'-dimethylacetohydrazide (10 mg) as a yellow solid.

[0292] Step 5: To a solution of 2-[6-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-5-(1,3-dioxolan-2-yl)-2-methylpyrimidine-4-yl]-N',N'-dimethylacetohydrazide (10 mg, 22 μmol) in i-PrOH (2 mL), HCl (5 N, 10 μL) was added. The mixture was stirred at 50°C for 1 hour. The mixture was concentrated and purified by prep-HPLC to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-6-(dimethylamino)-2-methylpyrido[4,3-d]pyrimidine-7-one as a pale yellow solid (1.2 mg, yield 14%). LC-MS: m / z 391.8[M+H] + .

[0293] The following compounds were prepared in the same manner as the typical procedure described for Example 34.

[0294] [Table 8-1]

[0295] [Table 8-2]

[0296] Example 40

[0297] [ka]

[0298] A mixture of 8-bromo-2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (25 mg, 73.3 μmol), 2,2,4,4,6,6-hexachloro-1,3,5-triaza-2,4,6-triphosphacyclohexa-1,3,5-triene (25.5 mg, 73.3 μmol), and potassium phosphate (38.9 mg, 183.2 μmol) in CH3CN (8 mL) was stirred at room temperature for 3 hours. (1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethaneamine (13.9 mg, 73.3 μmol) was added. The mixture was stirred for 3 hours. The reaction mixture was concentrated and purified by flash column chromatography to obtain 8-bromo-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (25 mg, 67% yield). LC-MS: m / z 511.7[M+H] + .

[0299] Example 41

[0300] [ka]

[0301] A mixture of zinc disyanide (23.5 mg, 200 μmol) and 8-bromo-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (25.6 mg, 50 μmol) in DMF (3 mL) was stirred in a microwave reactor at 130 °C for 2 hours. The mixture was diluted with EA (100 mL) and water (15 mL). The organic phase was washed with brine (3 × 20 mL), dried over Na₂SO₄, filtered, concentrated, and purified by prep-HPLC to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-7-oxopyrido[4,3-d]pyrimidine-8-carbonitrile (2 mg, 9% yield). LC-MS: m / z 458.8[M+H] + .

[0302] Example 42

[0303] [ka]

[0304] A mixture of 8-bromo-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (51.2 mg, 99.9 μmol), cyclopropylboronic acid (12.9 mg, 149.9 μmol), Pd(dppf)Cl2 (8.2 mg, 10 μmol), and K2CO3 (27.6 mg, 199.9 μmol) in dioxane (8 mL) was stirred under Ar at 100 °C for 6 hours. The mixture was diluted with DCM (150 mL) and H2O (20 mL). The organic phase was dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain 8-cyclopropyl-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (7 mg, 15% yield). LC-MS: m / z 473.8[M+H] +.

[0305] Example 43

[0306] [ka]

[0307] To a mixture of 8-bromo-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (30 mg, 58 μmol), (4-methylsulfonylphenyl)boronic acid (15 mg, 75 μmol), and cesium carbonate (60 mg, 184 μmol), Pd(dppf)Cl2-DCM (5 mg, 6 μmol) was added under nitrogen. The reaction mixture was stirred at 100°C for 1 hour. The mixture was diluted with water (50 mL) and extracted with HCl (3 × 30 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel flash chromatography eluted with 0-8% MeOH in DCM to obtain 4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-8-(4-methylsulfonylphenyl)-6-morpholino-pyrido[4,3-d]pyrimidine-7-one as a pale yellow solid (2.1 mg, yield 6%). LC-MS: m / z 587.6[M+H] + .

[0308] The following compounds were prepared in the same manner as the representative procedures described for Examples 42 and 43.

[0309] [Table 9-1]

[0310] [Table 9-2]

[0311] Table 9-3

[0312] Table 9-4

[0313] Table 9-5

[0314] Table 9-6

[0315] Table 9-7

[0316] Table 9-8

[0317] Table 9-9

[0318] Table 9-10

[0319] Table 9-11

[0320] Table 9-12

[0321] Example 74

[0322] [ka]

[0323] A mixture of 8-bromo-4-[[(1R)-1-[3-(difluoromethyl)-2-fluorophenyl]ethyl]amino]-2-methyl-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (30 mg, 59 μmol), 2-(tributylstannyl)pyridine (32 mg, 88 μmol), and Pd(PPh3)4 (14 mg, 12 μmol) in toluene (6 mL) was stirred under Ar at 110 °C for 2 hours. The mixture was diluted with EA (150 mL) and H2O (20 mL). The organic phase was dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain (R)-4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-2-methyl-6-morpholino-8-(pyridine-2-yl)pyrido[4,3-d]pyrimidine-7(6H)-one as a yellow solid (2.5 mg, yield 8%). LC-MS: m / z 510.7[M+H] + .

[0324] Example 75

[0325] [ka]

[0326] Step 1: A mixture of 8-bromo-2-methyl-6-morpholinopyrido[4,3-d]pyrimidine-4,7(3H,6H)-dione (136.4 mg, 0.4 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile (138.0 mg, 0.6 mmol), Pd(dppf)Cl2 (74 mg, 0.1 mmol), and Cs2CO3 (260.0 mg, 0.8 mmol) in dioxane (10 mL) and water (2 mL) was stirred under Ar at 100 °C for 5 hours. The mixture was diluted with DCM (150 mL) and water (10 mL). The organic phase was dried over Na2SO4, filtered, concentrated, and purified by flash column chromatography to obtain 5-(2-methyl-6-morpholino-4,7-dioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidine-8-yl)picolinonitrile (110 mg, 75% yield). LC-MS: m / z 364.8 [M+H] + .

[0327] Step 2: A mixture of 5-(2-methyl-6-morpholino-4,7-dioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidine-8-yl)picolinonitrile (36.4 mg, 0.1 mmol), K3PO4 (63.6 mg, 0.3 mmol), and a phosphonitrile chloride trimer (34.8 mg, 0.1 mmol) in CH3CN (10 mL) was stirred at room temperature for 3 hours. (R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethane-1-amine (18.9 mg, 0.1 mmol) was added, and the mixture was stirred at 80°C for 2 hours. The solvent was removed. DCM (150 mL) and water (20 mL) were added. The mixture was stirred for 10 minutes. The organic phase was dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain (R)-5-(4-((1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-2-methyl-6-morpholino-7-oxo-6,7-dihydropyrido[4,3-]pyrimidine-8-yl)picolinonitrile (15 mg, yield 28%). LC-MS: m / z 535.7 [M+H] + .

[0328] The following compounds were prepared in the same manner as the typical procedure described for Example 75.

[0329] [Table 10]

[0330] Example 77

[0331] [ka]

[0332] Step 1: A mixture of 2-methyl-6-morpholino-3H-pyrido[4,3-d]pyrimidine-4,7-dione (16 mg, 61 μmol), phosphonitrile chloride trimer (21.2 mg, 61 μmol), and K3PO4 (32.3 mg, 152.5 μmol) in CH3CN (3 mL) was stirred at room temperature for 3 hours. Tert-butyl N-[[2-[5-[(1R)-1-aminoethyl]-3-thienyl]phenyl]methyl]-N-methyl-carbamate (23.3 mg, 67.1 μmol) was added. The mixture was stirred for 3 hours. The reaction mixture was concentrated and purified by prep-HPLC to obtain tert-butyl N-methyl-N-[[2-[5-[(1R)-1-[(2-methyl-6-morpholino-7-oxopyrido[4,3-d]pyrimidine-4-yl)amino]ethyl]-3-thienyl]phenyl]methyl]carbamate (5 mg, yield 14%). LC-MS: m / z 590.8[M+H] + .

[0333] Step 2: To a stirred solution of tert-butyl N-methyl-N-[[2-[5-[(1R)-1-[(2-methyl-6-morpholino-7-oxopyrido[4,3-d]pyrimidine-4-yl)amino]ethyl]-3-thienyl]phenyl]methyl]carbamate (5 mg, 8.5 μmol) in dioxane (1 mL), 4N HCl in dioxane (3 mL) was added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, basicized with 1N NaHCO3 (aq.), extracted with DCM (30 mL), dried over Na2SO4, filtered, concentrated, and purified by prep-HPLC to obtain 2-methyl-4-[[(1R)-1-[4-[2-(methylaminomethyl)phenyl]-2-thienyl]ethyl]amino]-6-morpholino-pyrido[4,3-d]pyrimidine-7-one (1.5 mg, yield 36%). LC-MS: m / z 490.8[M+H] + .

[0334] Example 3. Biological assay a. KRAS::SOS1 AlphaScreen Binding Assay This assay was used to investigate the efficacy of compounds in inhibiting protein-protein interactions between SOS1 and KRAS G12D under defined biochemical conditions. A low IC50 of a given compound was observed. 50 The values ​​indicate high efficacy of the SOS1 inhibitor compound in this assay setting.

[0335] reagent: Purchase GST-TEV-SOS1 (564-1049) and His-TEV-Avi-KRAS G12D (1-169) from Viva Biotech (Shanghai) Ltd.

[0336] • GDP (Sigma, catalog number G7127) • AlphaLISA Glutathione Acceptor Beads (PerkinElmer, Catalog Number AL109C) AlphaScreen Streptoavidin Doner Beads (PerkinElmer, Catalog Number 6760002S) • Assay plate: ProxiPlate-384 Plus, white 384 shallow-well microplate (PerkinElmer, catalog number 6008280) Assay buffer: • PBS, pH 7.4 (Gibco, catalog number 10010023) • 0.05% Tween 20 (Sigma, catalog number P7949-100ML) • 0.1% Bovine Serum Albumin (BSA) (Sigma, Catalog No. A1933-5G) Assay protocol: Dilute the SOS1 inhibitor compound to a final starting concentration of 1 μM. Serial dilutions of the compound are performed using a Tecan D300e digital dispenser in a 1:3 ratio to achieve nine different concentrations. Transfer 100 nL of the compound solution per well to a 384-well assay plate, encompassing two series of concentrations ranging from 1 μM to a minimum of 0.15 nM. Mix 10 nM (final assay concentration) KRAS G12D, 5 nM (final assay concentration) SOS1, and 10 μM (final assay concentration) GDP in assay buffer, and add 5 μL of the KRAS::SOS1 GDP mix to the 100 nL compound solution in the assay plate (final dilution 1:100 in the assay, final DMSO concentration 1%). After a 30-minute incubation, AlphaLISA glutathione acceptor beads and AlphaScreen streptavidin donor beads are mixed in assay buffer at a concentration of 5 μg / mL (final assay concentration), and 5 μL of the bead mix is ​​added to the assay plate. The plate is kept in a darkened incubator at room temperature for 3 hours. After 3 hours of incubation, the signal is determined using Envision (PerkinElmer). The excitation wavelength is 680 nm, and the emission is 615 nm. IC 50 The values ​​are calculated and analyzed using GraphPad Prism.

[0337] [Table 11-1]

[0338] [Table 11-2]

[0339] b. Cell proliferation assay The objective of the cell proliferation assay is to investigate the efficacy of the compound in inhibiting SOS1-mediated proliferation of cancer cell lines in vitro, in a defined cell setting. 50 The values ​​indicate high efficacy of the compound in this assay setting. It is observed that the SOS1 inhibitor compound exhibits a potent inhibitory effect on the proliferation of KRAS-mutated human cancer cell lines.

[0340] The cell proliferation assay will be performed using the human cell line NCI-H358, a human non-small cell lung cancer (NSCLC) cell line possessing the KRAS G12C mutation, under three-dimensional (3D) ultra-low conditions.

[0341] Materials to use: • 96-well transparent round-bottom ultra-low adhesion microplate (Corning, catalog number 7007) • 96-well transparent flat-bottom white polystyrene TC-treated microplate (Corning, catalog number 3610) • RPMI-1640 medium (Gibco, catalog number 22400105) • Fetal bovine serum (FBS) (Gibco, catalog number 10099141C) • 0.25% Trypsin-EDTA (Gibco, catalog number 25200056) • Penicillin-streptomycin (Gibco, catalog number 15140122) • CellTiter-Glo 3D cell viability assay (Promega, catalog number G9683).

[0342] Assay protocol: NCI-H358 cells (ATCC, catalog number CRL-5807) are grown in cell culture flasks using RPMI medium supplemented with 10% FBS. Cells are incubated at 37°C and 5% CO2, with subculturing twice weekly in a humidified atmosphere. For 3D cell viability determination, cells are trypsinized, counted, and seeded into 96-well ultra-low adhesion plates. The day after seeding, serial dilutions of the SOS1 inhibitor compound are performed using a Tecan D300e digital dispenser to evaluate the concentration-dependent effect on cell viability. The concentrations of the test compound cover a range between 5 μM and 0.76 nM at nine different concentrations using 1:3 serial dilutions. Two 0.5 μL serial dilutions of the compound are added in a series. After 3 days, the effect of the SOS1 inhibitor compound on cell viability in 3D format is measured using the CellTiter-Glo 3D cell viability assay. Luminescence intensity is determined using Envision (PerkinElmer). Analyze IC 50 The value is calculated using GraphPad Prism.

[0343] [Table 12-1]

[0344] [Table 12-2]

[0345] Example 4. Comparison of biological activity and liver microsome stability Compound I-18, disclosed in WO2019 / 122129A1, was prepared. As shown in the table below, this compound exhibits very poor stability in human liver microsome assays and weaker activity in H358 cell assays. Surprisingly, when the CN bond between the tetrahydropyran ring and the bicyclic core in compound I-18 was substituted with the NN bond in the compound (compound I-18 vs. Examples 1, 17, 29, 30, 43, 53, and 61), the human liver microsome stability of the compound dramatically improved. Furthermore, the H358 cell activity of the compound was also significantly increased.

[0346] [Table 13-1]

[0347] [Table 13-2]

[0348] [Table 13-3]

Claims

1. Compounds of formula (III-A) or (III-B) 【Chemistry 1】 The pharmaceutically acceptable salt or stereoisomer (In the formula, R ２ｂ , ２ｄ , ２～６ , ２ , ２ｃ , ２ , ２～６ , １～６ is hydrogen, halogen, -CN, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, -OR ２ａ , -NR ２ａ R ２ｂ , -C(O)R ２ａ , -C(O)OR ２ａ [[ID=​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ R ２ａ , R ２ｂ and R ２ｃ These are, independently, hydrogen and C １～６ Selected from the group consisting of alkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R ２ａ and R ２ｂ Or R ２ｂ and R ２ｃ Both of them, together with the N or P atom to which they are bonded, form a 4- to 12-membered heterocycline or a 5- to 10-membered heteroaryl; R ２ａ , R ２ｂ Or R ２ｃ The C represented by １～６ Alkyl, carbocyryl, heterocyclyl, aryl, or heteroaryl is optionally selected as one or more R ２ｄ Replaced by; R ２ｄ In each appearance, hydrogen, halogen, oxo, -CN, and C are present. １～６ Alkyl, C １～６ Haloalkyl, -OR ２ｅ , -NR ２ｅ R ２ｆ , -C(O)R ２ｅ , -C(O)OR ２ｅ , -C(O)NR ２ｅ R ２ｆ , -SO ２ R ２ｅ , -SO ２ NR ２ｅ R ２ｆ ,-P(O)R ２ｅ R ２ｆ , -NR ２ｅ C(O)R ２ｆ , -NR ２ｅ C(O)OR ２ｆ , -NR ２ｅ SO ２ R ２ｆ , -NR ２ｅ SO ２ NR ２ｆ R ２ｇ , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; R ２ｅ , R ２ｆ and R ２ｇ These are independently hydrogen and C １～６ Selected from the group consisting of alkyl groups; R ５ is hydrogen, methyl, or ethyl; R ６ is hydrogen, -OH, halogen, -CN, oxo, C １～６ alkyl, C １～６ alkoxy, -SO ２ R ６ａ -, -SO ２ NR ６ａ R ６ｂ -, -P(O)R ６ａ R ６ｂ -, -C(O)NR ６ａ R ６ｂ -, -NR ６ａ C(O)R ６ａ -, -NR ６ａ C(O)NR ６ａ R ６ｂ -, -(CH ２ ) ｓ NR ６ａ R ６ｂ -, -O(CH ２ ) ｔ NR ６ａ R ６ｂ is a 3- to 12-membered carbocyclic, 3- to 12-membered heterocyclic, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl; the C ６ alkyl, C １～６ alkoxy, 3- to 12-membered carbocyclic, 3- to 12-membered heterocyclic, 6- to 10-membered aryl or 5- to 10-membered heteroaryl represented by R １～６ is optionally substituted by one or more R ６ｃ ; R ６ａ and R ６ｂ These are independently hydrogen or C １～６ Alkyl or R ６ａ and R ６ｂ These, together with the N or P atom to which they are bonded, form a 4- to 7-membered heterocycline; s is an integer between 0 and 3; t is an integer between 2 and 4; R ６ｃ Each occurrence is hydrogen, -OH, halogen, -CN, oxo, C １～６ Alkyl, C １～６ Alkoxy, C ３～６ Cycloalkyl, -NR ６ａ R ６ｂ , -SO ２ R ６ａ , -SO ２ NR ６ａ R ６ｂ , -C(O)NR ６ａ R ６ｂ ,-P(O)R ６ａ R ６ｂ , -NR ６ａ C(O)R ６ａ , -NR ６ａ C(O)NR ６ａ R ６ｂ ,-(CH ２ ) ｓ NR ６ａ R ６ｂ or -O(CH ２ ) ｔ NR ６ａ R ６ｂ And; R ６ｃ The C represented by １～６ Alkyl or C ３～６ Cycloalkyls are halogens, -OH and -NR ６ａ R ６ｂ It is optionally substituted with one or more groups selected from; R ７ and R ８ These are independently hydrogen and C １～６ Alkyl, C ３～６ Alkenil, C ３～６ Alkinyl, C ２～６ The alkoxy, 3-12 membered carbocyryl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; R ７ Or R ８ The C represented by １～６ Alkyl, C ３～６ Alkenil, C ３～６ Alkinyl, C ２～６ Alkoxy, 3-12 membered carbocyrills, 3-12 membered heterocyclines, 6-10 membered aryls, or 5-10 membered heteroaryls may have one or more R ７ａ It is optionally replaced by; or R ７ and R ８ These, together with the N atoms to which they are bonded, form 5- to 10-membered heterocyclines or 5-membered heteroaryls; each of which is optionally substituted with 1 to 3 groups selected from halogens, -CN, oxo, -OH, C1-6 alkyl, C1-6 alkoxy, -C(O)R7c, -C(O)OR7c, and optionally CN-substituted pyridinyl groups; R7c is independently selected from the group consisting of C1-4 alkyl groups substituted with hydrogen, optionally CN, or -OH; and, n is 0, 1, 2, or 3; The heterocyclyl comprises one to four heteroatoms selected from O, N, and S; the heteroaryl comprises one to four heteroatoms selected from O, N, and S).

2. R ６ is hydrogen, halogen, C １～４ Alkyl or -(CH ２ ) NR ６ａ R ６ｂ And; R ６ The C represented by １～４ The alkyl group is optionally substituted with one or more groups selected from halogens and -OH groups; R ６ａ and R ６ｂ These are independently hydrogen or C １～４ The compound according to claim 1, which is alkyl, or a pharmaceutically acceptable salt or stereoisomer thereof.

3. R ５ The compound according to claim 1 or 2, wherein is methyl, or a pharmaceutically acceptable salt or stereoisomer thereof.

4. R ２ is hydrogen, halogen, -CN, C １～４ Alkyl, C ２～４ Alkenyl, 3-6 member monocyclic cycloalkyl, 5-6 member monocyclic heterocyclyl, phenyl, or 5-10 member heteroaryl; R ２ The C represented by １～４ Alkyl, 3-6 membered monocyclic cycloalkyl, 5-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl may have 1-3 R ２ｄ It is optionally replaced by; R ２ｄ In each appearance, hydrogen, halogen, oxo, -CN, and C are present. １～６ Alkyl, C １～６ Haloalkyl, C １～６ Hydroxyalkyl, -OR ２ｅ , -NR ２ｅ R ２ｆ , -SO ２ R ２ｅ ,-P(O)R ２ｅ R ２ｆ COOR ２ｅ CONR ２ｅ R ２ｆ , 3-6 member monocyclic carbocyryl, 3-6 member monocyclic heterocyclyl, phenyl, or 5-10 member heteroaryl; R ２ｅ and R ２ｆ These are independently hydrogen and C １～６ A compound according to any one of claims 1 to 3, selected from the group consisting of alkyl groups, or a pharmaceutically acceptable salt or stereoisomer thereof.

5. R ２ is a phenyl or a 5-10 member heteroaryl; the phenyl or 5-10 member heteroaryl has 1-3 R ２ｄ It is optionally replaced by; R ２ｄ In each appearance, hydrogen, halogen, -CN, and C are present. １～６ Alkyl, C １～６ Haloalkyl, C １～６ Hydroxyalkyl, -OR ２ｅ , -NR ２ｅ R ２ｆ , -SO ２ R ２ｅ ,-P(O)R ２ｅ R ２ｆ COOR ２ｅ CONR ２ｅ R ２ｆ , 3-6 member monocyclic carbocyryl, 3-6 member monocyclic heterocyclyl, phenyl, or 5-10 member heteroaryl; R ２ｅ and R ２ｆ These are independently hydrogen and C １～６ A compound according to any one of claims 1 to 4, selected from the group consisting of alkyl groups, or a pharmaceutically acceptable salt or stereoisomer thereof.

6. R ２ These are phenyl, pyridyl, pyrimidyl, imidazolyl, pyrazolyl, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyridine, or triazolo[4,3-a]pyridine, each of which contains 1 to 3 R ２ｄ It is optionally substituted by; R ２ｄ These are hydrogen, halogen, -CN, and -CH ３ , -CF ３ , -NH ２ , -S(O) ２ Me, -OCH ３ , COOH, CONH ２ , COOMe, -P(O)(CH ３ ) ２ ien-CH ２ CH ２ OH and -CH ２ CHF ２ A compound according to claim 5, selected from the group consisting of the above, or a pharmaceutically acceptable salt or stereoisomer thereof.

7. R ２ is phenyl or pyridyl; each of them has 1 to 3 R ２ｄ It is optionally substituted by; R ２ｄ These are hydrogen, halogen, -CN, and -CH ３ , -CF ３ , -NH ２ , -S(O) ２ Me, -OCH ３ , COOH, CONH ２ , COOMe, -P(O)(CH ３ ) ２ ien-CH ２ CH ２ OH and -CH ２ CHF ２ A compound according to claim 6, selected from the group consisting of the above, or a pharmaceutically acceptable salt or stereoisomer thereof.

8. R ２ H, F, Br, CH ３ ,-CN, 【Chemistry 2】 Selected from the group consisting of (In the formula, R ２ｄ These are hydrogen, halogen, -CN, and -CH ３ , -CF ３ , -NH ２ , -S(O) ２ Me, -OCH ３ , COOH, CONH ２ , COOMe, -P(O)(CH ３ ) ２ ien-CH ２ CH ２ OH and -CH ２ CHF ２ Selected from the group consisting of), A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or stereoisomer thereof.

9. R ７ and R ８ They, together with the atoms to which they are bonded, 【Transformation 3】 A heterocycline is formed by selecting from the group consisting of -F, -CN, oxo, -OH, methyl, isopropyl, methoxy, and -C(O)R. ７ｃ , -C(O)OR ７ｃ The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or stereoisomer thereof, which is substituted with one to three groups selected from pyridinyl groups optionally substituted with CN.

10. A compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or stereoisomer thereof: Table 1 Table 2 Table 3 Table 4 Table 5 Table 6 Table 7 Table 8 Table 9 Table 10 Table 11 Table 12 Table 13 Table 14 Table 15 Table 16 Table 17 Table 18 Table 19 Table 20 Table 21 Table 22 Table 23 。

11. The compound shown below, 【Chemistry 4】 or a pharmaceutically acceptable salt or stereoisomer thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition for subjects having a disease and / or condition in which inhibition of the interaction between SOS1 and RAS family proteins or RAC1 is therapeutically beneficial, comprising a therapeutically effective amount of the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt or stereoisomer thereof.

14. A pharmaceutical composition for treating cancer, comprising a therapeutically effective amount of the compound described in any one of claims 1 to 11 or a pharmaceutically acceptable salt or stereoisomer thereof.

15. The pharmaceutical composition according to claim 13 or 14, wherein the pharmaceutical composition is administered in combination with at least one other pharmacologically active substance in a therapeutically effective amount.

16. The pharmaceutical composition according to claim 15, wherein the at least one other pharmacologically active substance is an inhibitor of MEK and / or its mutants.

17. The pharmaceutical composition according to claim 14, wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer, and sarcoma.

Images